var title_f25_55_26480="Ectopic ureter thru vaginoscope";
var content_f25_55_26480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic ureter through vaginal introitus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Urethra. (B) An asymmetric ridge of tissue was observed coarsing the length of vagina from the level of the cervix to the introitus. (C) Note the smooth contiguous rim of hymenal tissue, which remained unchanged after vaginoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26480=[""].join("\n");
var outline_f25_55_26480=null;
var title_f25_55_26481="Apical 4 chamber LA myxoma";
var content_f25_55_26481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial myxoma seen during echocardiography from the apical 4 chamber view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large, partially calcified left atrial (LA) myxoma (T) was found incidentally during a chest pain work-up (left panel). The tumor shows very little motion during parts of the cardiac cycle. Although the tumor appears obstructive, a continuous wave Doppler (CWD) shows no mitral valve (MV) inflow tract obstruction (right panel).",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RA: right atrium; RV: right ventricle; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26481=[""].join("\n");
var outline_f25_55_26481=null;
var title_f25_55_26482="Capillary leak in dengue";
var content_f25_55_26482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Capillary leak in dengue virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 428px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed model by which dengue virus (DV) produces a capillary leak syndrome. Monocytes (Mo) are thought to be the primary cellular target for DV. Serotype crossreactive antibodies (Ab), present at the time of second DV infection, bind to virions without neutralization and then enhance the entry of virus into monocytic cells expressing immunoglobulin receptors (Fc&gamma;R), as show in the left side of the picture. Serotype crossreactive memory T cells, also present at the time of secondary DV infection, recognize viral antigens in the context of class I and II major histocompatibility complex (MHC) molecules. These T cells produce cytokines, such as interferon-gamma (IFN&gamma;) and tumor necrosis factors (TNF) alpha and beta, and lyse DV-infected monocytes. TNF-alpha is also produced in monocytes in response to DV infection and/or interactions with T cells. These cytokines have direct effects on endothelial cells (EC) to induce plasma leakage. Interferon-gamma activates monocytes to increase the expression of MHC molecules and immunoglobulin receptors and the production of TNF-alpha. The complement cascade, activated by virus-antibody complexes and by several cytokines, releases the complement anaphylatoxins C3a and C5a which further increase capillary permeability. Interleukin-2 may contribute by facilitating T cell proliferation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26482=[""].join("\n");
var outline_f25_55_26482=null;
var title_f25_55_26483="Potassium citrate (powder or solution): Drug information";
var content_f25_55_26483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium citrate (powder or solution): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/14/37091?source=see_link\">",
"    see \"Potassium citrate (powder or solution): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/40/40579?source=see_link\">",
"    see \"Potassium citrate (powder or solution): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urine alkalizing agent:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder: One packet dissolved in water after meals and at bedtime; adjust dose to urinary pH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: 15-30 mL after meals and at bedtime; adjust dose based on urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/40/40579?source=see_link\">",
"      see \"Potassium citrate (powder or solution): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urine alkalizing agent:",
"     </b>",
"     Oral: Solution: 5-15 mL after meals and at bedtime; adjust dose based on urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-K: Potassium citrate monohydrate 3300 mg and citric acid monohydrate 1002 mg per packet (100s) [sugar free; fruit-punch flavor; each packet contains potassium 30 mEq equivalent to bicarbonate 30 mEq]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (473 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-K: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (480 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor; contains potassium 2 mEq/mL equivalent to bicarbonate 2 mEq /mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dilute with water prior to administration; doses may be chilled to improve palatability. Follow dose with additional water or juice.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metabolic acidosis; alkalinizing agent in conditions where long-term maintenance of an alkaline urine is desirable",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal insufficiency, oliguria, or azotemia; potassium-restricted diet; untreated Addison's disease; adynamia episodica hereditaria; acute dehydration; heat cramps; anuria; severe myocardial damage; hyperkalemia from any cause",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients in hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severely ill: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients who are severely ill or in shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to potassium citrate monograph for information.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to potassium citrate monograph for information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Polycitra-K Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3300-1002 mg (100): $73.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13203099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium and bicarbonate, urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary pH: 4.6-8.0",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Litiasin (PE);",
"     </li>",
"     <li>",
"      Urocitra-C Pwd (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To potassium bicarbonate; citric acid is metabolized to CO",
"     <sub>",
"      2",
"     </sub>",
"     and H",
"     <sub>",
"      2",
"     </sub>",
"     O",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10066 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26483=[""].join("\n");
var outline_f25_55_26483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212994\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213006\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212996\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213004\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212997\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212981\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212969\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212984\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212983\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212987\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212972\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299920\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212976\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287310\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287311\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212988\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203099\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203118\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190110\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212986\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10066\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10066|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/14/37091?source=related_link\">",
"      Potassium citrate (powder or solution): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/40/40579?source=related_link\">",
"      Potassium citrate (powder or solution): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_55_26484="Guaifenesin: Patient drug information";
var content_f25_55_26484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=see_link\">",
"     see \"Guaifenesin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=see_link\">",
"     see \"Guaifenesin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allfen [OTC] [DSC];",
"     </li>",
"     <li>",
"      Bidex&reg;-400 [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; EX [OTC];",
"     </li>",
"     <li>",
"      Fenesin IR [OTC];",
"     </li>",
"     <li>",
"      Geri-Tussin [OTC];",
"     </li>",
"     <li>",
"      Humibid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Iophen NR [OTC];",
"     </li>",
"     <li>",
"      Liquituss GG [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; [OTC];",
"     </li>",
"     <li>",
"      Mucus Relief [OTC];",
"     </li>",
"     <li>",
"      Organ-I NR [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; 400 [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; [OTC];",
"     </li>",
"     <li>",
"      Robafen [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Expectorant [OTC];",
"     </li>",
"     <li>",
"      Siltussin SA [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Casero&trade; Chest Congestion Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control [OTC];",
"     </li>",
"     <li>",
"      Xpect&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Expectorant;",
"     </li>",
"     <li>",
"      Benylin&reg; E Extra Strength;",
"     </li>",
"     <li>",
"      Koffex Expectorant;",
"     </li>",
"     <li>",
"      Robitussin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11746 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26484=[""].join("\n");
var outline_f25_55_26484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016987\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016989\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016988\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016993\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016994\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016996\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016991\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016992\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016997\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016998\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=related_link\">",
"      Guaifenesin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=related_link\">",
"      Guaifenesin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_55_26485="Alfuzosin: Drug information";
var content_f25_55_26485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alfuzosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/9/37012?source=see_link\">",
"    see \"Alfuzosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uroxatral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Alfuzosin&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Alfuzosin;",
"     </li>",
"     <li>",
"      Teva-Alfuzosin PR;",
"     </li>",
"     <li>",
"      Xatral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Benign prostatic hyperplasia (BPH):",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ureteral stones, expulsion (unlabeled use):",
"     </b>",
"     Oral: 10 mg once daily, discontinue after successful expulsion (average time to expulsion 1-2 weeks) (Agrawal, 2009; Ahmed, 2010; Gurbuz, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Patients with stones &gt;10 mm were excluded from studies.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F131558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bioavailability and maximum serum concentrations are increased by ~50% with mild (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     60-80 mL/minute), moderate (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute), or severe (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Safety data is limited in patients with severe renal impairment  (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F131559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild hepatic impairment: Use has not been studied; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate or severe hepatic impairment (Child-Pugh class B or C): Clearance is decreased",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     and serum concentration is increased three- to fourfold; use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uroxatral&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablet should be swallowed whole; do not crush or chew. Administer once daily (immediately following a meal); should be taken at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the functional symptoms of benign prostatic hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13185686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Facilitation of expulsion of ureteral stones",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (6%), fatigue (3%), headache (3%), pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (1% to 2%), constipation (1% to 2%), dyspepsia (1% to 2%), nausea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (3%), bronchitis (1% to 2%), pharyngitis (1% to 2%), sinusitis (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angina pectoris (pre-existing CAD), angioedema, atrial fibrillation, chest pain, cholestatic liver injury, edema, hepatocellular injury, hypotension, intraoperative floppy iris syndrome (with cataract surgery), orthostatic hypotension, priapism, pruritus, syncope, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alfuzosin or any component of the formulation; moderate or severe hepatic insufficiency (Child-Pugh class B and C); concurrent use with potent CYP3A4 inhibitors (eg, itraconazole, ketoconazole, ritonavir) or other alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blocking agents",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Discontinue if symptoms of angina occur or worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or used with antihypertensives (particularly vasodilators), PDE-5 inhibitors, nitrates or other medications which may result in hypotension. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; contraindicated in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer:  Rule out prostatic carcinoma before beginning therapy (many symptoms of BPH and prostate cancer are similar).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Alfuzosin has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Use with caution in patients with known QT prolongation (congenital or acquired).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Contraindicated in patients receiving strong CYP3A4 inhibitors or other alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warning/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensive agent: Not intended for use as an antihypertensive drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F131566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Alfuzosin may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Alfuzosin may enhance the hypotensive effect of Nitroglycerin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F131549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food increases the extent of absorption. Management: Administer immediately following a meal at the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease alfuzosin levels. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take immediately following a meal at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F131536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Alfuzosin HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $421.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Uroxatral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $468.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine flow, blood pressure, PSA",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfsin XL (KP);",
"     </li>",
"     <li>",
"      Alfu-Kal XL (IL);",
"     </li>",
"     <li>",
"      Alfurix XL (KP);",
"     </li>",
"     <li>",
"      Alfusin (IN);",
"     </li>",
"     <li>",
"      Alfuzo XL (TW);",
"     </li>",
"     <li>",
"      Alfuzon XL (KP);",
"     </li>",
"     <li>",
"      Azosin SR (TW);",
"     </li>",
"     <li>",
"      Bearxat XL (KP);",
"     </li>",
"     <li>",
"      Benestan (PT);",
"     </li>",
"     <li>",
"      Benestan OD (PT);",
"     </li>",
"     <li>",
"      Dalfaz (AR, ES, PL, RU);",
"     </li>",
"     <li>",
"      Flotral (PE);",
"     </li>",
"     <li>",
"      Fozal (PH);",
"     </li>",
"     <li>",
"      Lafuzo (TW);",
"     </li>",
"     <li>",
"      Lura XL (KP);",
"     </li>",
"     <li>",
"      Profuzosin (PH);",
"     </li>",
"     <li>",
"      Ranfuzosin (SG);",
"     </li>",
"     <li>",
"      Uroxatral (CN);",
"     </li>",
"     <li>",
"      Uroxatral OD (AR, UY);",
"     </li>",
"     <li>",
"      Uroxatral uno (CH, DE);",
"     </li>",
"     <li>",
"      Xatosin XL (KP);",
"     </li>",
"     <li>",
"      Xatral (AT, BE, BF, BJ, CH, CI, CL, CZ, DK, ET, FI, FR, GB, GH, GM, GN, GR, IE, IL, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, NO, PH, SC, SD, SE, SL, SN, TN, TR, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Xatral LP (BG, FR, HK);",
"     </li>",
"     <li>",
"      Xatral OD (BR, CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, PH, PY, SE, SV, VE);",
"     </li>",
"     <li>",
"      Xatral SR (AU, EE, EG, HK, IL, PK, SG);",
"     </li>",
"     <li>",
"      Xatral XL (ID, IL, KP, TH, TW);",
"     </li>",
"     <li>",
"      Xatral XR 10 (SG);",
"     </li>",
"     <li>",
"      Zapros XL (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An antagonist of alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenoreceptors in the lower urinary tract. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenoreceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoreceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in BPH symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Decreased 50% under fasting conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 82% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP3A4; metabolism includes oxidation, O-demethylation, and N-dealkylation; forms metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 49% following a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 8 hours following a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (69%); urine (24%; 11% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agrawal M, Gupta M, Gupta A, et al, &ldquo;Prospective Randomized Trial Comparing Efficacy of Alfuzosin and Tamsulosin in Management of Lower Ureteral Stones,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2009, 73(4):706-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/55/26485/abstract-text/19193417/pubmed\" id=\"19193417\" target=\"_blank\">",
"        19193417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahmed AF and Al-Sayed AY, &ldquo;Tamsulosin versus Alfuzosin in the Treatment of Patients With Distal Ureteral Stones: Prospective, Randomized, Comparative Study,&rdquo;",
"      <i>",
"       Korean J Urol",
"      </i>",
"      , 2010, 51(3):193-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/55/26485/abstract-text/20414396/pubmed\" id=\"20414396\" target=\"_blank\">",
"        20414396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurbuz MC, Polat H, Canat L, et al, &ldquo;Efficacy of Three Different Alpha 1-Adrenergic Blockers and Hyoscine N-butylbromide for Distal Ureteral Stones,&rdquo;",
"      <i>",
"       Int Braz J Urol",
"      </i>",
"      , 2011, 37(2):195-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/55/26485/abstract-text/21557836/pubmed\" id=\"21557836\" target=\"_blank\">",
"        21557836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9105 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26485=[""].join("\n");
var outline_f25_55_26485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131552\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131553\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131571\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131556\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131557\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131558\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131559\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131530\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131518\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131532\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131531\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185686\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131569\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131535\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131520\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131566\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131524\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131549\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131526\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131537\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131538\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131536\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131528\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131539\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131519\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131534\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/9/37012?source=related_link\">",
"      Alfuzosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_55_26486="Functional upper arm brace";
var content_f25_55_26486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70631%7EEM%2F74136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70631%7EEM%2F74136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional upper arm brace",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a commercially available functional brace that can be used to immobilize fractures of the shaft of the humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Applying an upper arm functional brace",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFfAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDiUXipQtAHvUgXgV88ddxFXmnhKVRTwPanYDN1tcadNjnivL7rr7969S8QZGlzFeeK8tn5Ocda7cJ1M5kJGFpUOQQQCP1FJJ1ApQdo4613GQGMKMqcj1qMj1NPLl2+Y5puOaAG49KUA9qXBq3p0Jnuo4/U0pOyuVFXdjd0GyS1i+13Cgt1UHtVyTUZrh8R/Ko9qdcw+bIIVJEaDmmBYogRvCj1rym+d80tWetGKhGyEkdNv78qwrA1a0Ecgkj+41a8doLq6wrhkHUg1av7ZdoUKMCtIT5JKxlUjzqzON2Z6UbTnBrZurXapYDiqPk8ZNdsaikcMoOLsVQmacI8dqsLFnqMVegtMgHHFKU7bhGDZnRwk1dhg5GRWglsoHNTrGoHA5rCda50Qo9yCKAADIp0lurZyM1YCgU8LmufmZvymJcWpBOFqutu+eB+dblwozT7C3aQt5abz2x1raNVpGM4IwhCy8kYrvPhvB5lw4IJwO1c/qFvL5iRNH5eOuTXo3w/037JamVvvMKVSd4mKVjqIV2KAy8VaCZwQKNpwPSpAOAKwAZspQnWnhRmncHNAiMIPSk2AdqlA+tGDnmgCML8vYGgqe9WoogwJzyDSyRbgBVKLYrlMKOfSk2gmrQix3o8sA5p8jC5W2LzzTfLHc9KsmOk8oelP2bC5WZF5ppQZwKt+WPSjywO1Hs2K5T2cdOaaU9au+WPSk2D0FHs2HMUSvNNK45wKvGMZ+6KPLHoKfs2FzPKZ7U77M542gfjWjFbbz0Aqy1rz98D8KapC5jnbWzk866Y4GZOPwUU+a3aMAkjk1vrZrgnfj8Krz2rAAYz3p+yFzGCye1Js46CtZrZ/SomgcdVOKPZj5jMZCTyBTdh7CtAofSmFaPZhzGeUOT8p/KmNG2OFNaBFMIo9mg5jP8ALb+6aY0Rx9ytAio2FP2SDmZnmFs8CirpAzRR7NCuzmlFPA4pVWngVxGwKKeq+1AXipFWmBU1OHz7KRBnkV5NexGOV0P3lbmvZtvGK858Y2Qg1N2C4EgzXThp2lbuTNXRy+MsDio26k1OgOSKh9RXoJmLQwGnH3owc08DNO4WGYIrX8OoDeBj2FZ6xE8jpWx4djKXnJGGGKxrP3Gb0F76NWSQpFIwPJNZTEScM4Ge9asiqfMhkGDng1jXts9seeVPQ1yU7bHfUNfT5YII9kRDN3xU8zl0rP0O0xCZ25LVpuny1lOyloTHbUo7QVIIGKrPbL/CKuuMGkUcVSk0TKKZTitfmwelSmAx8xH/AICelWgOelOxnihzbGqaRVjcMdrDa3oalx7U54VYYIzUeJI+B86/qKG09h7CjinA4pAVYZB/xqCSbYfala4XW5ZZA/UVuaZGlvp5dD+9boBxWRYOLkhU5YnFeoaN4fSK0iM+C2M4pO+xlUascbpmiz3lx5sykknjOeBXpOmWa2lqqKOe9SQ2ioAAAKthaVzBjWHApQvy+9SBRS7RjOaBEeOtKBxUgHpRjjpQAzGAODQvBp5HSkAHr1oAvwxImnRv/wAtHZifpVZmw2MVYVv9GjX0FV2GX/GtpO0VYlK7E3ewp/BUHb+NcO/ibWmkcW+lQOgdlU+byQCQDVeXxV4hicr/AGVb+2Hz/WhRmxtJandnr6UEDswNeXx/EPU55ljS1tg54wQevp1p83jfXBKIRp8Eb+rA5P056UcsxWR6YEJpyQsxAzgeteb2Xj3UpLWWYxwbYiFYhOhPTvU6eLteuXZIFtgPK80kKOF/z2otLqD0O/kjMb7Qdw9cU0wsOa4K48T63HYx3EkkSq4JT5Bz7Vz5+IGvTS+WHVc9MRAn8arlla4vQ9Zbg9aburywa/4quIWuI7iNYhzyqj+ntUcGseKZw7i8wi4ySq4Oc9OOehpcsn1C6PWVdgODil8wnqTXlUureIUshMdQyeTt4VvpjFQJq/iOaONo7yT98CUBYDIBxQovuLR6nrwmPbOamVmb72a8je58UW7gTXpBXG75xjB//VVsa1rUQJmunRVznLenenytbiZ6ezkdKp3VzngDNeU6lrurSRA2uqysxbbgHH6msybUtajnCNqlznarHJPU9qfK3swuj1xuaAgPbmvLo38QOocamc9Nhn5z71LI3iG3QyzX7ZC52ibP6UOm11KWp6U0J64qMwsegNebx6pqYBaXUshBkr5p/LPTPsKsR6tqQi8z7RMFGM5fGc9KXL5iO/NufQ1G1s2OhrgpNbvnAxLLyOzGqt1dawceXdMAw4Im6/rT5V3J5j0Ew4OMGivMZG1SMgT6rMHPON5P9aKagnsxc51qinqKBTwPpXEdABc4p6r6mlAp6qfSgBFWsXxTpB1Cz3QrmVOR71voKkVTTTs7jPELiB4JyJFK9iCOlVZEKvz0NeqeINNimm3PGpz7VzN9okUi/uxtauyGKT3E6LtdHIiPNSxxEHkcVs/2JKAOQamh0p14cfiK1lXj3FGkzMt4A+OK17aARbWUAEVYhsvL5wPwqcx4WuWdW7OqnDlJJ4UmCzc9OaqXaRTQ+W3B7GtCxG8PEe/IqOe0AJGMGsFLlZ0PVFSxjEFsIw26rTL8tMgTHHpVl8BeaJO7IWhnzLTAOKsSKDkiosccVa2EAGRTgtCipMcVLKIyM1E86xH5sVMwqjcQ7sk5NONm9SJXHmSOfnAB9Vps0Q25cfL/AHhVFgbV8gbl61r+HEk1jUltgCE6nPIArbltqtjJyWzJPDFrOmoRziJ/JU53YJFe06RdR3lmskRJXocjFcfc6WsVxDY6OWjnkx5m1vlC9yR2ruNPtEs7WOGNQAo7VnN31MLk+3pinAfWnbaB17VADSOvFLgYxT8cdaMdOaBDcDtmjHvT8cnmkIwOTmgY0r09KPTinnnoKADxQBMn3R9Kgk43H0yatAYFU7slbadgOQjEfka2qbIlHlaxsJrZ4nMakndsbuO/41k6he35V7W3fzC829XXnnPP0HrT7dNQhR3jjYEAja44UGsO5edZgJGKurdQex681jSUr3bM9CpOzQXBYk785OTnNW2uJ9m+F2d+Cqn5sjGc5qG72SxRk/fBYPjp1qe2ldbOOKIMCm8/P8o59++RXRJqybHa6H2Ezpp7gLuDOCykdf8AOT+dWmmu/ti3KxpDuPWJuOgG39KZpsQfT5ArqJAQSWOAPT+tQxt5LtGJCVkKnle49Kxc9WjZUZVJN7JdTSljvNVimL4/duXMCLgjAxkYPU+lUXzaXiuqFNmFf1YHkjFd1pNlawWo8kqH28yMecfX0rmJ7P7VdxBZcgMT5jtjPQn8/emneN29CZaaRNfRAZhBI5WWBoyACwIbin3d5JaxT+TCgiO0KrAjBzgrgfzFGl24t70qIlQkfIwXjHTr35pfEOnG7iBxtRRl2yB9PrTpQ926ZFtLnPz3c0txPFuTEZJD/wASH6/hV/RY5ZYoXjJSFGOOPmJ9STWhp2lqESbYEEihii8YOOh+vWtSKARrhQMHpW0Ka67CUSlqY+1RKWZgwIK7Op+vtXO30sw/dE75WIVlwAAT2J78V1IVtvy5U88MKwtSSOOFzdBmAbezr94k4AAz7VdWKVrBJGXe2aWUPmZ86OQBWDcY78fSpJbO4uFQBm2uCWOMHAwQPzqKO2MxDSqTFnfsU53e4z9McV1FjEPJ+UYUdM1jCa5+R7k8qbM22tWVUlkySP4x1HsRWXqs04d5I1LoOjMcqo/p9K6k5VG+UEDoo5zXNT+f9pNqYmYSNudxwF9hVyg4JJu6E42Mlbh5bpVdzPEx2DK7R68Y98VpGNZrSTMsivjILchfYHvW2LGFcApkjJy3OSe9QxQLOZSUwuDGf8R+dV7KzTDkMSzWV1OJWBXAwOSBTb6SeImTzFIBwI1/h/Gt9LNIQWQbQetVTZbmO7DDnk0nTUddGwcDLU25G6SWXe3JGOhorRkigZv3igsOM9M0VdmuocrN9RTwOlKBTgvSuA6Byj0qRRxQq1PBGzuqgEk8DFCQyWysbi8cpaxPK3UhRmnPazQz+VNGyOOqsMGvWPBHh/8AsuxF24zK4BOaseJbOS5haez2Nx88boD+Vbyo2jfqQp3lY8T1e3G08dK5e4iCucdK7jW4irNkY9q5W6jG4muNM7DLC4PSlZfyqcpTCtFxpFWReKhZatuvaoivFUmWiqAQwKnBHcVbEkjrh2B98c1Bjk1KnSm2MQJg02bpjtUpIqGTk4pxRLZXYcdajKnNWCvpUZHNXcSGL15p3akxSjikWgxkU1lyMGpRS/xZouIy7y32rzzmr3hWU2V+hiGXbgD1NMvGRceYeTVe2ISUOrZOcg1qm3HUzlC57f4f037JAZpiHuZvmd/6VsYwKoaDMbjSrdx3UVpdjxWTdzltYTAoC5FOHTpTgv1oAjx6il24pQOcc08gn1NADMcE0Y4pxBpMEUAJilVfmGKUg85FOAO4U0BLjiszWW2aVeN83ETfd69O1apHymsLxUzR+H70xttfYArehJFaVSVszy+UXb2dw9szqEBWQdGK+ozXK2CiSOdZmKOiM2TyT14x/WurmluWknu2RjFsKN2B9MfSuX1NTcTSTx4Tpz6571NB2tGxCRLplvFGEmvHCRZyFA3EmtsOdXTbBCY7dDkvjt35+nYVzunxRvKqtvuGUZEad8epru9OY29uki7UjAyVXgfhXPiJ+zlfd/l/wTshR5ldHn8pYyGO2aSSBZCVOMEj3rtvD+mxS6VFKyeZIeSTwQa56HTWudRuorRhIYX3Bd2GI9B6kV3Ph61lsrRkl4CEgZOSe/PvRiZKcVGLObW/KyjfWMi27kJvI/hrAjsikkb2cgIZW+crt5/rXcpcm4yPLOOnSsS4tYoZZWlnZYt2cKASvsD+FZUZSd1BaByIdb2920COzZOOucZ+tAtp2fL7Tz61oQ2lt5KyB7mXcAcliP0qYpbkf6onHua6KdKtbmjYVkZS20yybtye/wA1LEhDN++Ax2DmtFhAQf8ARw3pimgrnAtUP4Vs6Nd9RcpSMAI5ugB14Y1W1Cw8yAGN965+bGWzmtXJB4t0APGdoqKcs67GCgf7IrN0q/wtiaRjLChYBSI5DlstwcDitVEDKN0gzjs9UL22eeaENDvkDbsA4AHP+NVdaFxLc20cfkqqplk3bcHPU+vpzShSv70Zbf13Ha7sbDKy8LID/wACFIIiFwG59yM02xMkVnEskSu4GNwH5VDNdO10IvJdVC7tygY/E1rKFSmuZy0/rzBRu7IcyOUIL57dRToISoJJAJAzjviphLHj54+3JxUcbISTjHcAnFDpT3cvwFa5FM5XBZQAPesm/v3EbCBc453EcU/Ur+OTdGCAo7g9apXM8cSgs5KbegpRi07XK5e5j3UkzSAyK+4jnnFFJdSwSy7irucYyFPHtxRW6Wg7noyjNSKpPOKEWpUU8CuVFCqtdX4E0dr/AFWORl/dRnPI6ms/w/oV5rVwIrNB7s3AFe0eHdA/se0jgdUEoHJU9a6aNJt8zInKyNZ4ALQRp0AxXMXZktJz1212Ua5TBFY+sWBdSyiumS6mKZ5t4t0RL+BrmxXEo5ZB3+leVX8JjlZXBBBwQR0r3KeKSF+4rkvF+hLqcJmhVUuV5yBjd7GuKrRT1idNOrbSR5U68GoinpVuaJ4ZWjlUq6nBBqLZmuM7E9CsyVGy8dKtstMZfWmhlFkAPSkxirTqMe9RYq0FyGmsMVK2AeAaawpolldxz0OKjYY4xU7Z9aYwqgRCMelL1pOQakXrQVcQA1LHGScnoKfFHnqaZcO8mILUEsxxkdTSSvoFzKvUM1wSAdo4FNhiZGxiusi8G6/JbCWMQqSMhGIyaLXwxrEkyxzWLKxOC2Pl+ua2vZWDmieheCmL6Db57Ct4A1S0WxGn2EduOqgZNXwBjGKyON6sMdKcoz60DAwKUc5oEMxznFOwc9KcAOP1pcDPSgBvUdKQdaeMUg5PegBrfrTkOXANHf0p0YPmD0prcCVx8hrB8VwNcaO8KHaXdBn2Bz/SugkHy1geKJDHYJt+8ZBj8jTxDaTa7CWx5r4p1I2SpZRoBCyfOSvWuUtBJOPKghM247iCMAfj6V0moj7VqE3mxLnBXnnHTnH+etWbWJLdUIUBDxwMVj7Z04K+5tSoOpq9jG8P6Y8V3JIzDz1GAo6YP+cVv2ruropbBkYqoxznGajsARfeZGODxioTbSR+NotzN5PltIqk8DIwcfjXLNe2lJyeyudjn7GHs0tyt9lv9I1a4uFuUkE3z/MMF89wPUV2cbtcacjwFN5GflORn0qjfRNdxYgwlzCQ6HHTNOsDern7SqBnOTtHT8qlVVUXNL0Z5004z1ILq4urO3V1Ta8iMwZvUHA47cVyE+pyy3EwkDsp4ynZvX3r0O+MRt1S72FScDd09f6Vw+LW2LlJH2ruSNRyWweRn6ZropSjtFEPc6fw6WlhDSxhHT5SQcg5APWtSZC0bKr7W7Mvas7SLyFbZYTNCXPKhEKkD396t6rL5WnSyINxQAkDvzXM6s6dXTbsVFX0KUljOyr/AKS20HOOBj8quQw7hkHcR1IOea5GTXpFaCViWQ/fRRwO351vaPciSNJIf4mKmvXli3Ts7blum7GoVbBP8+ax9SineGSWzZRMi5GRz7D0rVm1Vbe5aKePbxxg9TXO+Ib25Mc83MA2BkHfg9SO9aSqwnJJPXsYa3sGhm+Yf6aypIzHcSvI7gH2qto3mTXqkhZ2ZnEjgZVxn+XpUOoSXKWBuJnhaW4bPmRN1BH8sfzrT0G/j8pdlsIE3AOV6M2O3pTjONNOT2fUtJ8tzUkh8uIk8bRnOarKu9Y2BwOHIPert5IHtZUxgspAI7Gsu6dktlVuGQYJHf3FKVenUSlF3JincfduBDJt2lx0BNZbvJIEjcYY5yVPaomkaSRQh4xjd/jU0O1GMku4sF44wDWTqOepry20My4s1Wd3lPy4wAKzLi3lEipgkuPkLHovUn2rS1CR3YhAR3LHoPaoLFvMkRCC5J6E4yB0A9qpO2pLQyG3QIMtEoPQOhJ/+tRXQxX1tbKUkjhlkzlmPPPtRV8xNjfjWun8J+GrjXbjC/JAp+Z/8KzdE0ubUrxYYlJGfmb0Fe4+HbCPSdOWKNQGxzipo0ubVinKxb8P6JDpFskUCgbeprbkiWVRzhx0NULediOTU7TBR97mu9NJWMSZSR8rgBvboaR8MCDUHnCUYLYYdDUd1M0cROORSbAp6hpsUwJAw1ctqOnvETkcUuqaterKSjsFFZUutXMg2ytmsGUji/GWhCcvc2y4mXqB/EK4Recg5BFevzuJck964TxTpHks13ar8v8AGo/nXHWpfaR00alvdZzRXmmMKduDLkGg8gEVzJHWiFlBFQsO+KtMveoJAeapCK0i+tRHrip5B+dQNnJqkIaQAe1RP14qRhxTMZb3p2C9hgX1p4xSkUj9MDqaBrUZ9rhZ/KDlT06da7nwVoH70XlyhwPuAjr71ymiaPLeX8PlI3ysCWx0r2O3TZEi5zgYq9EtDOq7aIlxnGOKcqjigD34p6gcVJgAGDSjjpSrzSjtQAYzR608AE9KMfSgBo4+lOHQUpBFHYUAJgHtQvWnAZNJ+FADWByeOKdEP3q0h68VJAMyn2FVHVoTHy9K5nxjcrBZRLgNIzHYD0B9TXTyjgVxvjm4VXtYGHLgsCfrSr9SqaV1c4q4jWANLK+M8sW71ClwL0+XB9xeN3+FTeKbQTaOj5PmRup/A8H+hpmlRi1t8cZxmvOunDme56MJttpLY0LWEJgD+Ec/Wp9QjVfFGn9y9vJx9MEVPplsRB5shCocsWb0rmE1r7T43in3YgAMUeem3H9TU0YSqynbZJ3MKs7tWN1Lz7PqcySZBAXGO/WtoSxzKGQ7X7j096wNUaNtXtVwMyggnOAOe9TLqDQ3f2aGBoh1aZxyfpWMG1qjSdLnStuUvEM83ktCI1k3DlSGUE/7JrCkvGtdLWxnjRTGhJK4OWJ7/ge1b3iTYV8m7Xc+d0T9Bj0/OsSxe3fVPNvBEF+6i9eeMH+dd1KSindHKsJWbulo+pJZtJfvINIimTy2QAnkLwcknt1rqXhlMLK4GNvzqSD26VS1iW2srSN40VHmB2sOACPcVgPrV5FcLMrxuxTZIGfAOOhq/ZwrK0i44SduZaiz6XJbyPJb7pEBzs69Oc4+orQ8MMVnYo7NuJkfOFxnPasmbWJL6OCNDslzmRl4Cn2rUsJ5heRJLO/luhO4KNxIPrWbnOnpNGtSCkrotXs8LTOlzIRIDuTpg+mDWTe6g1/dxNNGoSEgN5inbtz+ucdqm1+0hcrMszRhDtfvWXuiceXLK5h3D5gcY54PPpV03GolK5zOjUb0i/UnuIPNil8qb/Q4JMIhXlVYEjB79OlR6dI/k3BbzEtd4GQdu4gDisZb65TcEd0ilYs4bnJwQB/X8as6ZeRlZ4Yy0SBNy87ufTnvxXW6b5bPVHLLflOqmv3tNKaZEdmWIkeYOuOnSm6dq89+v2e8sWgZUJLZyp9MVkWUjyWptUxLLLx5rn7q9wf8KvRGSLyy0j/u8RkjuT3IHtxXHG9K8OrHFs2dG0c3N+5GDEg9OM1vNoEaxjd85zmpvD0awafGRgF/nJ+ta6uu4Hjjitac3bU9CFP3bvc4q+8OSSkqqn5uSB3rLk8PPbKx2NuPp1r01bhEXG0Z71XupYJFPyISeOldCmuopUjye40/Mhydh9BRXb3dlC0xJA/KinzEeyZ7B4P0UaZZoWUeY3JPvXVg/Lg0lvD8gAHGKl8ggZFdyVlZHnN3IwD2qVYSR1pFBB5FW4aaQFCRHTkClS7XbsmHHrWsYg45qtPp8b57VTiwMLUtOimjZ0x+FcZqFl5UhxXpIshEpw3HpWPq+mwzqNg8uT9DWUolJnncmVNVpgsiFWAINa2o2jwSsrrgismYFazaKPPfEumNps5mhGbZzzj+E1kxTg4r0q7hS4haOVQyMMEGvNvEOmSaRc74staseD/d9jXJOnZ3R1Uql9GPLg0wkEHNUUuQR1qRbgdDzWVjW45wD2qBhT3mB6VHv3HpTAaR70jkKPeiUkKccVSyzN3NWo3E2Ss+OhrR0K0W8u1SQkL14rOWE9W4HvWx4fO2+kXBUx4Bzx1qkkS3ZXPSNJtoLWBUgQKv861kNYdoxSIMHIwM+taunTNOHO5HVcbWXvxSaML6lsD0qRQcUiinAcc1IxcECnfw1hape3EV8Y4XKqAOKrf2henpJ09QK1VGTV0B059qMcVyNxrGrROPLSOSLGWLYGDSxeJbx3VPsqs3fa60/YSC51p96O1cyviG4aSMfZxscgb9ykc8Z61IfEU6D5rGY/Rcj+dT7GQXOjwKUAHHasO11t5mjU20is5I+ZSNuBnmtwge9TKDjuA0jmp7YZL/AExUWMjOKsW4wp7U4L3hPYbN2rzP4qXX2e6tSpG4KP0Oa9Nm615F8VJF/t1FGCwjAIIzgev61NVJuwnsWILi1u7BQGDNPH93qVFUp7qy0mNTqBZt33FUZLVy9hc/2XbrcFTkyFce2KbqN5LrDM7gKkY+VR6etecsMnPX4T1YRvDR6s6drptct3G6a3hI4jC9h6muN1KAWN5F5cischlwcnFLFqt7bWhtY5cw9AGGdv0Paq9ipurl5LmZQUHQ9Tn0r1qXLRptLbscUouL97Y6nVnDxwZGcpnNO0iHa6tcSCJSh2hjntmswT7o8tIpQA7T3A9D7itaKSC5sLWQXUk8yQMqgR5C/jx0ry1T5Y8rPQrYuVPDw5Fvf8yPxDcl7wwOMmMZBPI5rGhW2NxHI4+RGG7HB9q0pAWtUlvXaS6YAK2NuFGRyPU8GiwsrQ2MiTkFnGSwPzcHJwPyralKEH713/Wo5YmccNF23OiW/tJrN4pkj8lV2neOCfb1rz6+tDbugkTYSPu5zmtm4nS2vI1lDZjA2jOVJ9TWdOzXjtNITkdDjivZUaVlJbHBTlNJxXUTRrLz2YbsKe/eu0jtUeMBkyRgg/SuY0HEj7FxuGeT3Fd8IF+xRBT8yjr6mvMxtBynzJ9Ng57KxyOusGibafvfKfz61y7wzGKdoJtzRYJGPU4ro/EGYHeKTglxgeufSsWJ1sJ5LcqeP3kjBh8xwCMD0/WubDRlCNrano1cRGjRXLuylBAyFhKQ5Pc1NBp0ih57aVQiMCyseo9qbEbiUnzI/LJOVxyCK2EFt9jUhCZYiWkjZsA/8C7g9K6alSadjGvKhRjGpFXb1X6mXNLMjL5WNo4xj8au2LXE0wYRiGPglnbqc46fWmXWwNmHgtggN1Gexq5bwNcxWyPKiYYfKr7ixyO351nzWXYrGypxpxnTW/Q9KjmEcEajsoFIbv3xUE0TBNyZPqKz2cr1FVaxmmajXnbvVeW8AHDc1mPKevOKz7u4688D2ouNs0JL8bzlqK5qS7beeKKeorn2bAPlHFWNoxUMQIFTqp617KPDGGLPalUbetTgcUFRVcoCxtTyMioQCPpUig1SAY6Aj3rOvYuByR9RxWswyKhkwY8MDiolG40zk9Qso7qMrKoPow6iuH1XT5bOUq6kqejdjXqFxACSUrJ1CzSeFo5Vyp/SsJRuUmeWyrjiszUrSO6t3imUMrDHNdTrWlyWcn96M9GrElXtWTXRlpnkWq6fNpl20bAmMn5W9RVF5GQg84Nen65pyX1syMMMOVPoa88uWWxvhBNGC6nuOKyULuxuqmmpVWUnFWYSTXa2F1b3NmsU9pB04dYxXIeJW+ya0WhGyNgG2gcAjr/KlKFnYuMuZFi1spbqQbVO3PJxW3Y2gTEcdqJJBn5s8EA81p6FcLcS2sVsQySjfvXpwO/8qrXYjttRltTI4DFlBBAyfr/npV0Z+zjzrUipDnlyM5PWrN/tVsIwVXL4DHOOmM1oaehS9WXcpDxgHHUEHv8AnUs0bXJtSHLDc+D1JHGP5UrW0lpIpL7kkyV4xTrz56nN3/yKo0JRp2Wyv+B2Vs4MCDrmtvRoVSzOwBQXPFczphZokyO1ddpibdOiJzzk/rWDMyZRinj60m0eppwAxxUgc1qgY6jKwBI4/lUSOBkEYrSu9puZDxkHFUpYDJkiuyL0Qhk0kYXDIWVgc9MVEkFihXZbIjqcg7ACDVmCNgg3DpSb43mAYeZGM5APNKU7BYzbi1t5HjaBIowvDgxZ3DI/+v8AnTHs2zIsa2vlk7gpRhnGcZ/Amt+CC3mLsoYKTjk4NSGyhLE8/nVKXURiaNaSJqKuVhCYONhbPPsa7bPOTisiztEjuA65J6c1rk57VhWd2NCjGOnWp4fu1X9OtWYfuA1NP4glsMl+9XknjuN28R3TNDIRwFYL1G0VD8QvFer6d4uvrbT7+WGCPYAgwQDtBPUe9ZP9v61NZi9fVomWSXyf3kP8ezdjp+H1rpngJzV77kt3Ri6pBNHpYMqOu2cjke1U7SZlKqOM8EVu6rqesedcWeoQ20pgbODAcP8ANtBXHqf5etZyzXBWW5OnW6+Qy712sp+bOPlz04NQsBUUbaP5nZDExSSfQoTRssrYBKnkVEinzW4OCOf6Vdk1dGZSbKIKuflDHBq8dRhslT7XpJUyLuQ+Zzj8v50fVsRHTl/FCqVqc4vUm061MN9llHzMnB6EcV2l1Z20QnMVuiSlSw2DGTjr+lcu/iXTo5Inm0q5ibarp845Hr7itL/hNdNuZVb7Fe7wDwoU/wBa4KuX4pvma+5iq1qUoQhHojGlS9ti8F9FvjZldXY5Y+ozV7UZYZNIimEKrJEAQFGMEn/9dM1bxHpN+Ldf9Ji8ttzZjBJ/WprjW9FntzGlzIgdNrh4jz+Io+r121J03cipUj7OKT2voc8myTUo5Y0d4WwzRHk98gZ/Sp5rNxpt1u3HO2SCRRgFCwBB9+aar6ct3Gsd6rQYClmBFTzvCPPt7S+ha1ZcqHkGQcg4rojCo5pNNbbp9zTESjGMPZy3WvqQ6YI4zF8+B0DDjjtXXabJ5aMiSs6rz8xzz9a8/t+bjyg8fJxksMVa028uxcRiLc4D7MK3B9q9Svh/axtcxUjpNejS8vrbzVy2MHnHrg1yssFxYXTyX1uskNwGj5H3SD6fqK7I6bc3WoQZUiNPmLdj/nFXb7SxcyJvG5UIZVx0NeFiarw00mrpoqo4zjHujh/satfw24PlK6A8E4AOQP5ZqSGxjubu6jDLlCAgVsLIQefxOM1tXGlzjWEGBsCKiflzVmTRYNsckSb5UbLEcc89vqc1CxPKrvd/gbYhrlgl2Oe8Q2sk1yoDIDIwUFT9wZxg+9aFlNFZ3FoqbJQmBvAAOe547VRl0mS0uDDLLvE8mSwGCA39a2xpUkFlbRQSAGJiQZOeo7VE6sIpRvdE4h+5Tb7G+mppIPlJU55B6io5Z0klK8GuZ1q8EBjkAaOXHzd1J70lhfm5DzRHOFww9DXV0ubRlodGyoAW6VganIDkKQT+VQXOr4jZM8471hT3gduZgKag2VzIsSSbXIyD+NFVkiSQbvNzRV2Qrn3ggAqUEdqhjGanUACvWR4o4AmnqtIGFODZqkAu2gDFLnNLTASkUAggml4pR3oAp3ECkkjg+1ZlxF1zg1tPg1Ru4lxluPespoaZzeoWqSxski7lPUGuE1vSns5CyAtCeh9PY16ZPCSvB3D1FY93CpDK6hlPBBFYSVykzyydMg8VyPizRhfW/mxDFxHyp9favStd0prVjJCCYT/47XN3UeQcDmsno7lo43wheJJEba5X50OOeop3jSyiOntPGuJYmGT/ALJ4/nS6tYG0vPttspHP7xR/OteVotR0mVSAWMZ6Drx/jTn7y5kaU5crsY/gC1vbG1lMQ3S3KhkXui56/jkVavdNmFxObiQlgwcqQTt45wfxrsdMtrZLe2lhiVWEQAYDBxgcU640u1uJmlkDh26lXIzSpqN26oVZysvZ6HnupadKUtIIp1icOyqy8EDBODWGs93Bq0drcTM6g4IJyM4rqviHGukRWktsXc548xi2DzXB22oS3Wp2gl2/JJ1Axkn1pzglL3fhsaUq0/Z2b1uepaOSbZDz0rt7ZNlnEg7KP5VxOh82Ufriu7YY2jpjiuVkidqWkxjvSngVIjAuFZ55GzwSarl3VPlzkGniQ5Oc4PehEAJYOSCfumuxCLMTCSMAjrQLFGcMGdCO4qKO2xI5I4PI+fFWNhUHAkA9mqZK4XJLaBI1w/JDEgmpMqJTtC5qn5j5IVJDn1PSo1I+0SrcIxQqMMoPHrUt2Dc1LZgzI3YmtDp0rN0pQIYOvetM1nN3Y0AJ4qzGPkFVD2xVxPuiqpbikeR+MfAOsar4hv7+2e1MU8m5VaQggYAGePasZ/BHieOxitVtbWSKKYzrtlUksQBzz0wBXts7bYpHPRVJ/SvF9a8RGGZktrlmZsfJH97J7AitnmFWNopXBQuEmk+LY5/NfRd5yM7DnpN5v97+8fyqBk1+KOZLnQbsiSNYmYBt2F34IIzg5f8ATHQ10Hh3UtQuLRvtyzRSDAVw5wV7ZGevrXZeHHuXeUXExkG0EAnpnsaqOObXwoHG2h4lbLeafYzW0+k3BLFzuaIjO5NuDx2+8PemyaiH8RXOoXFvII5EdFV4wxQlNq5B4OOK+izULrCzbXWMt6MBWn1/W7j+JPIfPzahpdyLFLqNsQRrEWMeSMRkZOD8w3kHHpUOlXdpb63c3G5YovImSPYrAFmjKjA5IyT+FfQEmm2EpxJZWrn3iU/0qrJ4e0eT7+l2R/7Yr/hTWNja1mLkPDZJLHUo5Lm7xFdsCpVSR91FCEeuSDuP41Jdafpe27NtccqitEGccknlSfUccjg4PTpXskvhDQJPvaVbj/dBX+RqpN4D8PSf8uTJ/uysP61SxkPMORnl2qadYyW1xtdA0ctyyzIVGdoTYpA/vc4x65om0e3Ek6BIiyXM6h9pwUjh3YwD6/r+VeiS/DfQn+59qT6SZ/mKqSfDLT+sN9dofcKapYqn3YuVnmzaADGUhffK0Vuw8xSoDSkYAOcHr3rPbQpS1yILiGTyIzI+NwOASCMYzxj8iPfHpdx8MmK7YdZlC4A2tHxgcgcGqVz8OdXZ3ddbWR3GGZ9+SMEcnnsSPxNaxxcP5vwFyvseZRrerbG5j+0CBW2mRSdoPpmt2yt7zzdLt/7Uu47nUE3xhXJVASVXdz3I7dPetmX4Ya2gIjns3HoJCM/pSp4P8WWgiEUULmFSsTrIhaMHqFJ5HU/TJxVyq0p7SQkmjAtrnxG0sQinvGdztQbs5OCcc+wJ/CrNprPiB5YYxcSATSCNWkjG3JOOuPWry6B4ntp7eVtI8x4U8vcACXXaVAYg84U4pIbbxDaeSTos7eUIl5ib5ljbcq/n3qZKlPpF/cPUo3XiHWIp2iuBE8iHjdAOcHqPalHjLUcDfHatj/YI/rVgXGoW6eVcaVeoiptV1DCRTv353FTxk9MVjandSzWdtAYpY/K3l9w4ZixOfyOKTwtCo/egg5n3Oy17RorjRopotySOFdtp9QDTfBujeVZXzyFiG2quT3Ga37Ro20u0DYI8pev0FPlm8ixBQDYcnj0rw3Jr3eh6sYbNHl/iaE2906CufhlKOPMwyE/iK67V5YbyWQkjr3rmrqwOSUyR7V00pK1mZVYO90XkMZUYcD8aKzRBcAAISR+Boq+RdzPn8j9ChL6VIrZ71li5A6UG5ZuBXVc841xKo6nmniQVlw7vvMTUolPQU+YZoiUdqdvqnFvfscVaRNo+Y/hVJtiH7qjnYjAHenFsfdx+NRSXEfmAMckUNjQ1XcDkE1XvW3xHrVoXcTsFXANOcwuhEqgH2qXr1A5edprY7wSV9aiNzDcDD/K1dBNpu5C1u4YH+Fu9cvqVhJGxaJWVx1Q/0rNprcpEF5BlWDAMh4+tcPrumG2YvGCYmPHt7V1sV+R8knIpLqOOeMjAKkcisZIpHl9xBuyGGQeDWCuNMudrHELHgnp9K7DxMn9mv80bGJvuuKwL+3jvrI56MMg+hqE7FFxtWmtbaNoLb7REAB8jYI/Cp59ba3YLJZytkbgY2DCuA8y+0VWO1mtCcEMMr+HpWvp/mXlqtxFG4jPvRJ8mtropK+g3xrdx6zZRp5NxC0WTl04zxjpXG2ukNDNHJ9qtyVYNgkg/qK7zZOO8n5mnCKbjhifdc1jOtzW5dDSMeVWepseHoT5NshHLMOPbOa7R/vZNc74bt3XEkikEdM10fXNRe4mIcZ4pSPkOcYxQBn2oA45oA5hkMchDA4zwcdaleSMAcYPvXRFecGkKIeGUH8K09qKxiwyoV+eBmOeoI/xpjzQMOYJkI/2f8K2vs8J/5Zp+VMaytz/yz59iRT9oKxipNbLziQc91NWIp4cYEqnH941oDT4RyrSD/gWaPsMf95vxxS50wsxtiB8hUhl55Bq7xnPNQQwvG/LqUA4AXFWAcZqJO7GN6mro+7VQcnFWzwpPtWlLqKRm6xu/sq82NtYwuAfQ4PNeG6eLK0lYWytdTZ3C6kGACOoFe5X7+bZyrEfnZeK8wPhm/ilkaO0IV3ZsKQQMnPHNctZScbI6cOouXvFrS7ne8ccp2seAueT7iu08Oqd05OMAKoI6d64vTrC5ivfMmtJY1RcKCuQeOldz4fX91MwB5I6/SpoXiuVk10ufQ0pnMcZYIXI7DrVWUxy4Z4pBwTzweO361amR3QCN9h9cZqErdDpJEfqpFdCMSs4tV2OXkjZkHc5xz/8AXpwMYyBduGOOpGR3qY/ac/MsTDnoevFMPnMTvtUIPoQaYhmSAxW8HI4JAIHPBp4W43586MrgjG3v2phWPym32jdeVVevvURNsQoeCRNuQDg8DP8A9agCyhuMHd5LHjoSOe/9aaZLjoYUI9Q9QRi0IYJJIpPzdSDxn/GnP5LEul2ykEn7wOPwoEOEsvAeEjIzkHocHioftRA+eCZfoual+YoQl0GPBGQDSNHcbnIlTGMKNvT60xkBvYsHKyAgdCho+222ceYAfcVIv2sMocRMv8RGc1Gvneb+8to8NwWUg9/8KNBDvtEJYASLkjPXrUikMMqwI9Qc1WLqNouLdVB/iOMCnPIlpGSYikI5LLyB71Si3sguTHPqa57xZqcumQ25gijkaVipDrke1dGMMAVIIYbgfUVja9o39qSwMzqqxA8EZ5OOf0qlGS6AmrnDy3V1flQqLHPK23agwoPt7VL4pmlt7CO2gQ4VcFq6K701dKj+1vKsgXj7uNueK43xJq0bkpGy4H61lKLUtT0sM1KFzh7jcHJJOan0y4R5hFKeT60972GJmLKCTWbkzXQmjG3HTHetbXWoSsnodLJZwM2do/AUVVhvnWMAuwPpmisuVhZH2PC+/HNX7cKvJNc3b3Y45q4t7gjJr0TxTpEG/HpVlI40GWxmueh1RVXrWTqHiBpZHSF9sSf6yT09hTukB2VzeHBWDCjux4ArLk1M2rbWfzAf4815zfeIrhps+afLHRfaq0/iF5dq81Lk2NI9Hn1ja25Gqo2ptM5IPWuSs7tpEGST9avQyEnIXmkM2Yb145fmJwTW0l8JEHPSuSllwMmnwXjKcZNAHb2d2w4B4q1O0M8eyfGD0PcfSuSs9QwcnisPxT4hmtJ4yhOz1FPmsKx02s+HvOQy2jBpB+G6uU8yS2laOUFGBwQauaF42RnVJzwetdBqVja69befbSKJgOHH8mqX5DOL1izi1TT5IHwNw4bup9a88sNOvbV3ivVKIrFVB/iP+FehTCaxunguFKupwR/WsvxDavdWvmQN8y/eX1Hr7EVm4rcq5yF5GhSRL2MeXICo25I+hHY1oeGLe3giWBcFR93PpTntMN5jxlJMclGyrfhUUAZJQ6DAFRJaWHF2OnFrDxmNfyqZLeEDAjX64qO0mWaEMBzU4PPSuW1jYEULwoAHtS0dKPX0oAX8qX0pFxxxS568CgA69xS8Ac80Dr0oIJ4xQAKKUik4AwaD04oABn0o/maVSR0pO9AAfpQfpil7mkIzQA5QPxq3gEYNUe/BxipPNkHR/wBK0hJR3E1clFtEOAoFIbRCc4xUf2mcdDEf95T/AENKLyYAkwxN/uuR/SrvTZOo8WqgYwD9aPsoHQY+hxUbai6/espCPVHU/wCFH9rQL/rbe7j9zFu/lmi0GPUl8kgY7fWk8tvSkTWNLbAa9SI+kiMv8xVyGWynOIdQsnJ9JlH86fs4vZiuymUI7GmlT6Vsrp00gzFskH+w4P8AKkbS7scmB8fSj2XmHMYxFIRWq9jMOsTflURs3/55N+VL2TDmM1kUnJUEjviozDHjHlpj6VptaNnGxs09dLuHGVif8qXs2F0YslrCwwYlx9Kjks4nOSGzjGQxrak0y6AOIjkdjVGzt7xrlhNFGUH3QhJJ+oxWtLC1KuxjVxEKXxGe1mCzMJZgSSflbj8qz7vUrDSmU6hdTIjthGdSFzjpnHNeo6bbKIFLW6xN3GKp+J7GC70meOaNHULvG4A4I5B5oUOV2lqWpc+x588Gla1CspkFxD0VkkIH6VbsYIbWP7OrHyxyqsc4HoPasRrZ9PufNhk327/eUgBl/EdR9eferc0rxgvuOFBKn0rSnJTWg6kHB2Y/UdRhhuFBjuDt/wCeceRUT69p4XLs646743GP0rHtUeWRriY/ePGe1Vr64/fLGjEZbkjvVkGjqXiLTZrOWNXjkjYEMArHj8q8w1a2thZrPGFKyMcSgnpXoLs0dlIWI/DNcDZTC6t9SgkTckM5wPYjP881FVe6n2OrCz5ZW7nJXGC3NOtjsOc03U7QRzN5DMAeeKpxxzJx5jGp5U1udUrp7Gm8uTRVLMncgn3FFTyojmPraK5KkAmtO2kEqHn8a566jYKWXrTYNT8i3dpDytb3PMLurXMsUhhhOGbv/dHrXL6jqLonkxt+7H6n1pdS1JpUI581zlvYdhWckJlO48H3qW7lJAkrzEA1qWVlkgtkmjT7PkFhz7V0VtAiJycUWAZbJsAFa1vt4BBzWYzqHq3bXGPeqQjSaIMOmR/Kq5t8HrxTvtIGMvzTWkz360gB2EacnFZmoWyarayQH/WgZQ+9Xp4zInBzWeFe3mD46daTGcAWktbhopcq6nBBrpvDvia50uZSrlojwQa0/EWhx63bfabPat4o5HZ686na4064aK5jZGU4KtSTtox7nuN21n4j09ZoGVbhR8p9PY+1coC8MjRyjDA4INcnoOuvaSrJDIdn8S5rupZYNYtBcQkeco+bHcUBYxLu13uNn3PSsycqk3lqPl7nFbqHadrjjoaw9YeO2Zo4G3SH9BWctAS1HaTfILtoQ3FbynJ6155vNtcrKpIVuv1rJ1/xDdWGpwrGy+XIMfNnIPsRXPOLewq1WVON4q/4HrZNGO1ZXhy7e80uKWQ7mIBzmtbr3qDeLurgOmDSdjRSgUDFUc80q9aT8aAPegBd30NKp46Ugoxn2oAUn2pB2oHX2pRnIoASlakHWg+9ACLzngUZ9qBQaYCAjPSg8A0gHTNGDkc0AAx09aOh4JpTwTkZpDgk0CGsA33gCPcVBJZWsvD20J9yoqzx2z0ppoAz20eyzlIth9UcrUkdnLD/AMe2o6jDj+5cNVwUhwQcdaaYEKXOvRf6jXbo+0oD/wA66DQtR1gwynU7tLgEgR7Ygp984FYmATgHk11WhWMrFWAxGgxuPc+1XFyb3JdjQs47zHmtANnp3rVtpElX+YNELS2+M5dO/rRemMILmIgY+8B3FbIzHTQIwGR9D3FV44owzAqofvgdfenrPvAwflNQXJZMMByv6iqAmfCisHxNci30e9lJ4WFj+laElyGXIPFcN8TNUEGirbg/vLqVYwP9kHJ/lU3tqVBXaRzpfzYFDc5XFRby1o6sASCFOP8AP0qus6rABkDipJZhHZRkjLMN1ZYVu9joxOyZVkdooHUggdTWRGPMuAwPX1rQeQzyHK8AciksUDXOSBhR1Hauw5B2pqEsiCMDHbvXlnhe8C6rqCv/AKuVjmvSPEMoWzncZKqpOSfavINBY/bJGB6nJ/OqlHmg0VCThJSRr61bhZGeEgqe1YZJ9K6TUrIyIJIXC7uSnaucuz5BImJGPQVzqnJaHf7anNXuR5NFRLcwkZDcfSinZi54n1zblJlwcYrD163S2cHeCn3iv8hU5nNvJIjEjAyDXOatcySsodsljuNaNnnIYQZ5NzHrWlaxcDPaqVl0HHFbdrFnnt2pIbJoFKDAFXFyRhjgehohi6VYMS475piK4BVvl/WpQX6Yx9KkEYqUbUAJ6GgCEBz259akWVlOG59xUc17EnANU5LvJ+XgmgDRN0E47etQyXkbg5xmqDuzLgYrJu5ZYXJC4FJsdjobW5MUmUP4elV9dsrXWodtyuycD5ZAORWJa6md4D8c9a3EmjuIMg8juKW6A8w1eyutEvSrj5eoYdGFb/hnXTBIkiMTGeGXNbuoQwX8LWt6oeM9D3X6V53e2Vz4c1VUly9nMcJJ2P8A9ep2KWp67IY54lmhIIbqK5DxBaS2+oC6gBZJPvL6EVZ8N6gTC0THOz5lHqO4rcuIVnjI6qwyDS3QbHGzxLcQEp0bkexrlPEthJf2KtEha5t2yABkmu9mtvLcnGAfvD+tYt/Ebe5Ei/dbg1F3F3RVlJWNn4dzNLoUIYFWUYIYYIrqwea5PwUxR54s/wAWRXWd655blQ2F6UmaWg/jSKFo5FBxg5oGQO9ACrilAPakOB2yaAeTQAY55oxzS89TnFJ+NAAOM0nPejt1pDigBe5pM9qU4yaQYzQAo603v0pfoaQkZpgJ165owBnvmgUY9aADkc44pufalJ6ikoEKSDzikHOfSjPNdD4d0M3W24ulIi6qv96mlfYHoM8P6I946z3A2wDkDu1dxBEqKFUAAdhSwxKihVAAHAFTqoXmuiELGTdxBGCOazLuyaW7xwtsVyxDck+mK0JpwBgVnXFzgHmrdhIrHFu5jH3P4abdXQKdeRwaoXl+0kZjY/MhyD61g3WoPuIz14pXsMvT3QjlZc8HkV5F431xdV8TLDCd0FkCmQeGY9T+mK6Dxnq13baPcTWpIlAxu9AeCa8qsX2EuxJYnJJ71lVlZW7nRRj9o6l7sbQufmOAK1tTIXZGrc8LgVyWly/adXtYgCfm3ED0HNdT5LSXIlkXAzkCqwysmycQ9UgKeTCxLb+OneiF/s9szuTlucGlnXzHU5yq+lZut3O0pbxn5mPPOK6jnMzxRebdAunycuMV5/oUI8wkiur8fv5WhlAfvEDFY+hwgIjbSSQDTb0QG5GMwYCjI65Fc1rtqCGwuCea7CNDt4AAIxWPqkOQ2R8tAkeczRmGRkx7iitm5gHmnIop3K5j6t8QrZPbBwR5qjJHtXnt5KXkZjxk11l8hNqSxxJPhto7L2rnr20wMEYIrKRKKtnclGABrobK53YYmuQcNFJ3FaenXXIyTmkmU0dtbybxxwKvQptA3HNYNjd/JwMY9a1Uvflw5GKskuSOFU9M+9YmpX/lghck0XdwXyFJFYd25LH+tJjK01+/mE5xU9rqJz85zWZdr1NUlkZe9Rcqx2cF2rAdM1dZIriL5sHNcXa3RXqTW1p96QQOoPrVbisVdTgFq+4D5ak0y+2sFzWpf2guoGIGciuQkSS2nIOQQanYFqdRqMbhBKnKHoRWdJLBqFq9nfLvhcY56g+o96t6NqSvEIJ+VPTNQatp/lMXiPHWkxmPawTaRdIjtvQH5JP76/412eiXiTjyXIBHC+9c3BIs8Zguen8Lf3T60kDyWkzKThlPUUtg3Ojv4l85gMc1hahbb42jP4VYF8090HPXbVi7AljDrwamSuhrQz/Cjotw0b8SD9a64fnXB7za6isqcAnNdzbyCWNHXkEVzyRoiXtmijPFKOlSMBjpRQOvNHU/hQA4c4pADzSdKXpyKADt170EjdS56UZBycCgBMZFJkgetGTjB6UnIBwaAF7elI1GcUhpgHtScdMcmlPTNBxj6UAJ1xQeBRx60h7CgA4ParNhaS3s4it0JY9+wqriu70KJLOyXEYUvjL9zVRjzMluwWnh20ijRZE8ycHcWJ4HtW1EFUhOAfQVBeX0VlCON7Hoo61jG9mNws4Yh+uO2PSuiyjsZ3bOoJCDJqpcXGO9VvtyzRBl49R6Vh65rVrpls097OsUQ7k9T6D1qr3Ekac916msq+1CKCNnmlSNB1Z2AFeU+JPiReTl49Gh8lOnmuMsfoOgrzjU7+/v5C19cTTt1+diR+VZOrFG8aDe+h7ZceLdJk1FLa3vopp3yMJkj8+lVb7UY9hkBA4rxTTXeHUraRW27ZF5/Gu+1S63Qxqvv+PNEZ3FOmo7Br2p/aLG4jOCrIRXApIVjwcV0F/IFs5iTxsNcmZD5fqfSomuaxrS0TOh8JJ/pN1esCFiXy0Puev6V1UBYQhmkOT2NZGlQC1023tivzn53PfJrTikGN7EbU6A9a6qcbROabu7jru6Wzt2kbg4/Oua0xm1G/e4bcUB4qDxRqT3MnlLz6471teHrVbXSxI+RgZPHWrer5SNjkvH8gnuPs0fOxNx+tR6BqFn9migmlWG5QBSJOAceh+lRrnUNRu52IKkkAe1Zl5pxeUFRx+lF1ewHeebAsIJliVOx3isXUruy2Ei7hwfRwa46azeMkFfy5og0yWXJVcAdzV3Qia6u7UzHEoYeoBoqpJZsrYYYNFGgH0hd3gmlVyfVcfyqKaTcvzDkVRgsp2t5NwOwfMD9KVZsjC4wKyTApajEGGRzWdbyNHIOxFa9wwbrgVkXCbGzmpasXE6DT7zON34itdWDAHPWuOtJtpFdDaXAZBk800xNF6Zxjn86z7hd/3etWXfK461XbCNnOaYik6nGCKzrmAoxIreDxnhiMmqt1GmCAQfepaGYO8irVrcsjgZqK4jCmoAdvTrSKO60a8DgKTkGmeI9NR0E0Y+uK5iwvGhcHJrtLGYX9sY8gkiq3ROxxce6GTjgiugs7lZ4hHKecdao6rYzW87BkPFUo2ZTxxUjL17aNG25ORTZR5tsHx86cH3FSwXRKhWORTl2iQ/3W4IpAU7TmatBHIOM8VRtYylyyt1U4q4/BoGUtTi6OB71u+GrnfB5THlemazpk8yFl71Bo0pgulOcDODWMkWmdl+FL+hpikHkdKeRzjBrEoBnPtTgOabketAPpQAp9zxSjp60j/jSA8CgYvTmgHJNHUDHWozKgyM5I7ik3bcai3sSH8cU09M+9VnmyeSQKPN24Bb73QVPtEaexkWj702oPtMe4jcCR70S3Ua7Rnknimppi9jJE2enPelOSBUcT7+e1O7j6VVzNqwg4B4pTgkYHNG0kEjt+ldLoOlbNs1wAznlV6496qKb0RL0HeH9EB23F2vPVUP8zXVeSGXGOKjjBVRxn6VLJKEXrXRGKRm3c57V4TaTiRSSjccn7prPN0M8nFX9elLxECuFGswm+exMq/aUGdueo/xoejGlc6WbUDDllP1rzXxDb3up30h1aYSbfuKpwqr2IFdbHJuPNRX1ktzAdoG7+FvT/61G+g4vlZ5PqUBtHMZ6dQcdRWRM/XaOtdfqljNdTtaGJxcA/KoGSD/AIVNbeDCkYfUZlhJ/gT5m/wrmlTadonWqqtqcAjEXcPb5xz+NdffSfcUHoopNR8M2UcyS295KGjbdtcAhvy6Vzms63FZ3Mkc7bZF7da2hBowqTUtibX7jy7B1zy5ArO8OQC6uxNIP3UZyPQmsW5vX1SZeT5K1vafJ5Fv8rbQRgAVqoa6kOdo2R0LXBeZiDlieuaNQu/Lt8Fzt/nWZbzrFGZZenYA9axb68l1S+S1hOFJwSeiitk+piX9HtzqurhVBZFOWI7V1PjG/TStCMMOCzLtB71e8NWtppel4tlLf35u7GvPfGF+dU11IEbciGnHT3mBa8P22yz3Hq3Xjk0skeGIAPBrZs4PIswFOOOeKzrhcynnJNSloMrw2yPjOMZ5q/5MccRVADmmQIQpyOPpVrrH7eme9NIk567twZj8p6UVcuIt0pLLzRQB6Q2qY2pyFHGBVWKRY5XXPfvSJbBpsmjVgsQjkQdtpqPUYtxzytZl0xOc1ZWbMXvVWUZJoY0Rwtg4rZ06YZHNYY+Vqu2suwjNQnYvc6RyBHu6Gsq5uRypPNXLeTzI+OTVO6sncklTVshFL7UwPBpy3RYYJ4oksHA4FV2t5E4IxSGWJEVwCG5qrJHijLp1BxQXNIZGpx+FbOjak9rMpySM1jnrSocHrihaAeooYdXtQRjzcfnWBd6X5bnjFZOiao9rKuGIFd5BLb6pACGUS4/Oqavqidjj/sB/hNI1vLGORxXR3Nk0LYK1WcZ4YcUrAYhXMqSdyMH6ipXGasXMSqpKjGDVbORSGOjHFZ8i+VdkdjyK0VOKqX+1grj7yHB+lRJFI9G8O6PDqWkwzi5YMRgjbnBq1c+G5IkZ1uo9qjJLAisj4eX5S2mhY8A5FXfHet/ZtJkjRsErzR7ODVwu72OF1nxnpul3TwHfPIpwfLxgfiaf4e8Yadrk7wW29JkGSr45+mK8uVIL++aJiTLM+B+fPevS9C0LT9Lt1+zW0McmOX2/MfxqcUqdFKKWrLoRlUu29DppJVQnc39aga7PREP1PFU5ZtnCDJ9qElwMsOa4HUb2OtUYrcsNIzcuePQdKZJLsQ4FRGU5ycAU03SB/mxgVGr3NUktijqN7OjoscTN3wBXL6hq2pS37LHG2QNuF5211l3qkK5xtrLbULVD8gRSe9aJ9ilIz9KTVXYb1Az6muht7S48wy3EpwBhQBwKq2+rQpIQGBx6VNbXV1qtwttYo0mPmcjoAKtR0BvU2rNsQqCeauBdzADJY8AU/QtCvbuAzMvlRgnHmAjNdTpGlLbIJZwGm/Ra1jBs4arSk7HLR3DQxvG52tzW34Pvzh7eRs45U1yusF/7QuIx/CxqtpN7LaalES3BODSVTllY2lHmgevNOAvFUrm5wOtZf9oL5O9mAUDJJPSuC8TeKZLzfb6c7JbdGmH3n9l/xrqukcag3ojQ8V+JyZHsdKIefo8vUR+w9TXnd7YSQP56yv54O7eDzn1rYtVSGAMEKE9QetZ2o3WcjNTdNXNlHl0Om8N6tFqkZRiqXkY+ePP3h/eFb3nCNeTXjdvcXltqkU+n589Tx6Y759q7ifWmubdWxtfowHY0oyM5ws9Daku41uGdFQSldofHP0zXM6rqjMWy1Vp71sEk/Wqyxx6nfRb5NuSBIo6vz1FNy0Jscz4m8RLYQn+OVvuqK80lup9S1B2mO53P5V0/xGaJtWC26BY1yAB064rJ0q3WOMSFArN19a6oJQjfqZvV2LdrGLaBY16k9fWtE3AVVU9qzmYGQDHC0xpwucnOKiw7mjc3hdMnjHStPwTo39qXRmnLLaxn5iP4j6VjaXp9zrN6kNuh8vPzPjhR616jBHBpNglraqFVBye7H1qrX0JZT8XarHp2nmK22qoGAB2ryWG8nSZ71QrkNlgRnFbfjnUHlnS3GSzHnnoKqWmlQLFI14/7/A8uIH5mz+H/ANeuqjS9o+WxnUlyo7DRNTW9t/LlikguAu4Dsw9R61FdZEofPBNW9Mstmn2zm482WNNjgHkZyRnIHoemarahxEjkYJbGa558t3yO6OidKpSfLUVmSQkFN2ST64qVmO3liB64zVaGQ7Rk8fSrCKHzgkD69aSMmVX+Zyc5oq75Sn+LH1op8ojop5So3LkGo033MTo7e4HvUENwJIxnnirtm8cb5YA47VluWZpbaffpUhG5c4qa+tWlvMwgbG+YVMYBGhDHnFAGVKMHpSxtxTrjhsZqJTg1my0amn3JjmXPSu3sliuYAeprzpG2kGum0C/2EAn9a0g7qxMkb1xpwxkCsi5tNmQVrqoJFmTNQXVpvBIGapok4e4gC54FZ0sWOldVfWBUnIwKxLiIISMVDQ7mUVIphqzLkk8VAymkUIM5zWhYajLbOCrGs0kjrRuNO9gPRNL8TRTII7oA9smtXy7a5G63kHPY15XG7Agg4rY07UZYSPmOPrVXT3FY6+8sGKNheSK56Pjg9Rwa3bDW94Cy4I6VMtrps0zSuSCxyVzxSsI5x225rMkkJdx2xXb6rY6a8CiA7ZMdRXFT20kFyySD3B9RUNFJm54TvfJkY5wGFc98Q9b81LhVk6HFSadObWSQN/CDXm3iO8lub24QN944HNT2LitWZ/hy+2a9bO77VDHn8K9aTWIwgJnG3Hc149/wj93ABObvT8rztW5Bb9KtR3Usi7XY5HHB4p4uPtJKSNMM+VNHq416FvljkUn605tYRBl5Bn615XGzAghiKsbmYfNN+HJrj9kdVzu7vxJEvCvWLeeIpZCfLJ+tU9E8OX2sP/oyN5Y6yPwv/wBeu90n4f2duA9/I87D+FflWk4olzSPOrzWJVTMshHtWSNYkMmQWA969i1fwJpV3CfIgEUmOoJrzDxF4Sl0+QmJzKoPTGMVpBR6jjUTNLRGS5t1ljlLknDD+6a7vw0L5ZVS2VgD1IFcT4UhewiRREDIxBwa958JXFnc2qAQCC6UfNGe/uKuEU3oZ15OJtaLHcraBJmYr125/lV5iEGCcjsfWmLMMY6H271WurgEH9a6LHGcXrgUaxMw/i5rAvhtmV17VqXcvm38zZyM8GqF9g8ivNqP33Y9GC91JmNrWqXtzMttLlbUY2qp/wBZ7k/0pYIVhUy3DAADPPQVegiSUbW7cj2qvqWjpd7Q8rCJeqBsA/WtPaJ6yFyW0RlXGpPdyj7LhbdfvOw+/wDSq9vZzahcrFAu5j19APU1pPpCBeJdqDp6CtvSjbWFoY4SPMPLuepq1UT3ZMovoinLYW2l2Zjjw0hHzv3Ncpd3q2s+4n5Dwwrq7/7POD5k7AH0riPE9ulhMk9pPv6/K4BFP2ieiI9k1uWC8l1MqwAuz9AO9b8enrpFl50xDXJySR/DweBVL4au09jdSzQqCHwkuPvDuPwrV8XybdOxnknaKuHvSSMJKx5nqPlOrNLGrbmJBPUY/wD11k3EIHMbDaehxWvqUkboYk5bBOfTpWCrsAVPSup7ma21IJflQ7TxVnQtJk1S5GflhB+Zv6CpLCwe9nCplUB+ZvSvQNA0+JESGJQqD/Oaad9CWaOl2kWnWiRxoEjHAA/n71l+ItQWG1cNgkd62b+VYVIbPy8da8q8Z6m11IbdTyx+Yqe1axRJjRztdam0sinG7kbSfl/z3966UWUCjz2UuwChNzf6oAjPfJHJx9OtUPCejy3uqwD5ooB9+4wCsZ/hzn64rWvrC7OpLbSyqI7VSsMjrhZVzwy+pPTFdNOUVFybNacOapGK+/a3UkFwGsbsWy3CyogxvXhSzdv73ydM1I+ItMsoi7yPyxLjnGeM1LcXBungtUVd6qBM6nqQfbsOwqO+izOmDyBXNWld2SS9AnNzerb9SeBjxk8e9aVqmQcYx9KyIWIIGMY9K1rRwG+bmoiZMp30rC4IUnAHaitXC5JEecnnIoq7kmfpN0WUozfMvT6Vomdh0JrmYJDBcK/YHn6VvRsDjnIPIrlual4XMhhJU/MlRm8crljUtlDubPGDVS+hMMxjHPcVV2A7zN5yaDxzSQRsF+YYzT3HGKljQqnirVnLscc4NUVPNSg4ORSTsytzu9GvfkUE10SzqyYFedaVdhGANdfp9ykgGTzW6dzJomv080EbSa567tuTkV2SIHXNZmoWe4FgKTQHFTxYJ4qm4Ireu7cqTxWXNEQeagpFArz0pMVYZKaFx1pDIsYqRGIp23IqSO3ZzwDQBLDcMvQ81bjupGP3iKrmEIMfxUw8kIn4mncRr20zNIo3E10smkrf6SCoHnqMqf6Vy2nx7SDXoWgc24HtQlcGeXaujWjpKycA7ZFI7Vx/iHw/G832+yf/AEWTll6lD6V7N450bzbaSeJeo+YD+deUwzNbSvGRlG+V0PQis2rGkJGUnw31m9iiltbmMwyANh3IK5rtvBvw/TSXaTVJIbx2AARk3KuPrXW6FNFPp8TQZC46entWkAaxnUk1ytlqKWpl3fh/SbqPy5bC3wOm1ApH4iq1r4Q0S1m8yOzDMDxvYsB+FbwGeTQOtZWRd2NSNI1CxqFUdABilOQPrS9c+tHbg0xDJQSjbeDjArlNS0S7vHO3aq9csa63HPWkPtTBOxxem+F5IZlub24KiI7ht4PFbdt4hs5Y2aQNZTRsRHK3CMPXPb6Gq/inUPLiFpGfnf759BWXbor2pVgCCMHPQ1HtXB2WpsqftFeR3umeJodQjMRkjNyg52MDvHqKfcX5MbknkA4PrXjk+mfYphPYnyp4zlWQ4rrtF19NUtHhnIjv0X5k6B/cV1wqKSuc86XKy5FIDISe9R3bDaaiToDTJ2Gzk15retztRVjmKSHBxSXV0ygkE1n3k3lvkVXa7WXHPShMLFmS4c28jSNhccVzN14k8klVYk9KXXdVCgxRng1j6NqUGn6n500KyowwQRnH0reELkydloLLrN9ctiNZT7BTW9pWgXGtSRjUXkghUZC/xH/CuusDZ6haJeWSL5cvTjkeoq7ZQFLlmPXb/Wt/ZpK5zSrN6FmytYbK1jt7aMJEgwAK5Tx1OTthVsAfePpXYHg4P515X4vv2kuJ2cgAsQo9hWlFamMjnzOrXojTGCCB+VQx2ZknOeEHU1nRTYvFk7Bga6CM/vuPu+1ay3JWxpWMaRqqIMLXYaVGIbUyEAnHFcvpUe+dRjIzW/rt8ljYhQcMFrSCJZgeLtaWCN8N82OleZ2qvd3xZ+WY5NXNdvHvLliW+UGpPDsO+8ViOBWjdkSdHaaRqf2OVdMldTKuNgkMfPZgR0NaOleG72Bjc63MqHy1j/1vmOQP5E1qWl61pGoiyWI6Y6U52lunDz7vXBpqT5eULa3GRRQRIWt4UhTsB/WseZvNmlk6qOAa1b2bZCwGQOnTmsidhHbYGNxrOWw0SRBgobPBqfzCo3AEMO4pLcAwx7eT7U2Veu7HHNJAPFw/pu+pFFUD16n8qKvUkdJFkE45HUVc0+QmIxt1Tp9Kz4rlh1+b61aiYFxJFww6rXK0ao1orkxjAq0t0j7XkTJXr9KzDggEdDUsG3OGPFNSCxteZFKv7v8AWoJkrMRzFKQD06VcS6DD5utO9xWInG1sU4ciklbJ4pE6VDRaLEMhUjBrodLvWBANcyDirlpNtYc4rSDJkj0OxuWK8nirskm5MCuY0u8BAzW/G6ugxWhBnXsIYE4rGuYBnpXSSrmqFzATk4qWgObkhxURirWmgOelRCEDkilYZVgtdx5q4yrBHx1pGk2DC1A5LnnmiwyGZj2+8afbRY+tOEeWyatQx5I4pAWbSPpXc6Cu2IVyunwF5AAOK7bTYtiAYqkJl2aFZYWRxlWGDXhnjzSDpOsPsB8mT5lPp7V722Fj5rz34hWsd/YyLgeYnzKaU431HF2Ob8A3e9XhJHqK7M8eteU+Dbw2+sIrHhuK9VVgRmuOotTpjsP4xikHDUmRkUqkZqCrC5pGxng00kYOO9BwOtAWAcZqvf3S2lq0rkYA4B7mpuOcGuM8U3jy3jQhjsj4xnvSbsrjhDmdjM1K4eWfzXOWc5NTW8+IsA9feqcwDx/SptPs7mc7Y4mI9SOK5tWzrukiC9uACMnAzijSbMG9FweGHStOfRbqIB5Ysr3xzUSuIRtHFVeUVYhyjLY1WlCj2rOubvk4NVZ7zCnmsi5u+c5qCkP1G7AJrEmvjErbT1qLULv5j83Wsa4nL5wa1pU76ktj5ZRNIWcnPpVi20PUb66CW9rIAcfMwwBWbAkk86xwqWkcgKB1Jr3zToWhsbdZAplWJQ5Hc45rq2dkYVJ22MLRLcaVp9vZg58sfMfU9TWxYymWSUnoABVdbbL5YdTmrdiir5uOmQK1lpGxy3ux9/KIrWWTPRa8Q8R3Rmmck8kmvWPFlwYdMYZ+9mvFdUlLSEnFaUloKRmqcHFdVp582GJu5Uc1yeea6bw+++zA6lSRWk0Sjr9AQfaE7hec1zvjPUXurt4UJ2qcV0Gnny7aVwMHbgVyWpjdJIx5OaadkI5mZf3hFdD4Vt8tuxzWMYi0vrzXV6HBsC8EHrTb6COlggCMCf51LI5UEZ2qKEbcoHWoLpiSVwMe1WIqTt5rZHzL6Gsq+AluUjAx7AVfnkZM5I2+nes5XUSktuyenFRLUZfysRXax+XuKdceW8WWIZu4zVJpD5gCgYHfNO+0BQcjj1NADGxnjcRRTWkUnOR+VFAFINtNSpKVIKnBpsyVFnFYoo27K7R8I/DHp9atYO7ArnFfnitvT7rz12txKv6ipasPcuPCwj39xUSNU6yuflqN4ir4xQA5GOeatKMio47Y4BqYKVGCKBjWGKEfB60rEYqEmhDNmwutrDnmus0y6DqATXnkcpQ8VsadqJiK89K1jIho7zazNkDNNlU4wVpND1GKYANgmuh+yxTLlcVRJyc8QJ6Vn3ER7V2c2megqjLpv+zUgcc8ZHWlRBmumk0jPamJoZ3ZwaB3MOOEseBV62sZZCABiuhttHAxkVr2mnqnQUWAoaTpxjVSRzXR28W0DPQUsFuFHSpJ2EUZNUkIp6ncCKM8815/rE0l3dGKEFm5OBW74hviqNg1ieHJ0W+lllwWYbR/Wpl2Gjy+6ik0vWULgqA+efSvXdPjeeziljIYMo71D4v8M2+tWTPCAk68owpPBRlXSvs1wMTQHYwrCUe500p2LpSVTyppu5h1GK1cU1kVvvAGs/Zo25l1Rmb6XcMValgjP3cimxwKOoNHsrkynBFf5j2zXK32hXV1qczjCxs+R3ru0RQOlSBFB6Cq+rp7mSrNbHN6X4bhjAMq7m9Wro7ewghUbVFOxSs5Qc9K1jSjHYylOUtxLhIyu1lGK868Z2Bs2N1AP3J+8PQ13N1dgrxXPawyXdrNBIMq6kUqtNTjYdObg7nmd1eDb15rDvL3qM1FqFwYmZCfmUlTWRJKZDXDTo9zvcieaUvzmqxLMwRQSScAetaVhol/eyIqQMqMfvsMCvRvD/guzsvLnmBkmHOX9fb0re6WiMpTSHeB/DcenWKXF3Gv2xjuz6D0rr5W2xM3oCaAMKAuMDsKbLzGy44KmiO5zt3MmDUFZyD2FXbJt8BbP3mJrkt22YgHFdLoj501STnaWz+daz1RNjmvHl11jB+4oB+p5rye/Ylia77xlcM2ZW481i2D6dB+lefXLb26VtBW0JZUH3uelb/hlz5skeeuGFYaj2rR0eXydQhbsTt/OtJ7Eo9AQ7NOkI6k1yN825z0rqbx/L08Ad+a5Kb5m46k0nsgI7a33SAkfnXV6aoQKoAI6VjWcOAGxmt61ULj+E+ppoTLYYq21jx2x2+tRXHzKdpwc+vFKsrA5cAsO9Vrl92SoPFU2Iz7uUrncVP1yazllO/jI9gal1G4+XacZ9e9U7dS5POfXiobGXEBwSSSevNPG5gDkYHvzSxoBHnIA9KYcO2MHAOMCgCZI9y5OTRVaQqrYAcfjRQIt3ERGRiqcseK2WUSpj+IVQnixWCZdjO5BqaCUxurKcEU2ROai5Bq9wOntbgTRh1+8OoqyJ+QzLnFcvZ3TQSBhyOhHrXQwyrLEHT7rCoehW5pJdKSB2qZpUZe1YynBwetShyB1p8wWLcuOxqszc0hfIqMmkBJnmpI3IPBqtmnq1CA3NM1BoJFO413ei64HUBm5ryxGwav2d68JGG4rWMiWj2y2vUlUZIOauKsb+leYaVr2NoJrq7DWkYAbuauyZB0v2ZD0FOW2X0qlb6ijAc1dS7Q9xRYCVYB6VPHGBVYXa+tMe9UcA0WAvPJtFZeoXBKHmmyXee9UbyT90xz2oA5TX7jkrmsK0uitzhT0NSazd5eR+y8D3NZ+ixtNcKPfms29Sz03RnaWAbucim3Ygs73eCFaQYYetWNMjFtaGRuABXIiWTVdekYMfLjNN7agnZnTR3kTHBx+dWNoflDkVSg09J4Dg4cEioJFutOfcMvH3FTZFc7NqKEEcio76Py4iyjpSadqEdwuQefSp9RlU2rA9cVViLlBGBUGnLJVOzk3wfShmINIZoLIPWob2ZUgY5FUXmIFY+s35SBhmmAyW8Bzz3NZV3dEseazEvCz8mpoInuH3H7tS2Ox5h4pRl8Q3USAks4Kgd8jNb/AIX8JSPMk96uQOQnb8arePIRa+JLa5Tuin8VNepWTo1tE8YG1lDD8RXPUWtjfmdkPtraKFVCoMgVa3Y+lR7sgUFsGosQSZ9qCxPGOMVGWHbrSEj1zTEcVcfLeMPRiK19JuANHnz1EjLWVqq7NRk/3jRbSbNG1Lr8kitx7ituojl/GtzveMZHToO1ce6ZzjtWnq85nuMk8elVfLyo4FbIhkCx+xpzIYyGUcg8VYjjBHv61dt7YzSRIR1Yc1ZJvapL/ocakchB1+lc6gPmcngVqa5JvlYD7vrVG0TJGRkUmM1bKMADsOta0SkA4K7QKoWqMVBUkAdO1aUSDktwTVxJZHIpz0O3rxVG5cc5/Or7gYbORism+dgrKx+XsDQwRi3r+dNgDjvircG3ZtX86oHHmFgvX+VXYpF2YwRz1UVAy0BkZwG47VDuVEJUncO2amaQLB8hyTxUdnCJDukBGT94UxFYGWQbju59qK21UY45HvRRysBIZMGpbiMSKGX8apg4PFWYJcHB6VzPuaFGaLHaqUiVt3EQYZFZ0yCmmIzzxVzTr0277WOYz19qryrULcGr30YXsdYcMA68g85pQeKxdIviH8mQ5U9Patnp9KzatoUBNNJoJphNAD80oao91IG5piLKtTw1VQ1PD+lAF2OVl6GtC11OSIg5NYqvUgerUrCOttvEciAAmtODxPxy1cAHp4kI71SmKx6RH4kD/wAWKsR60rclq8yW4YdCamS8kB+8afOgsenJq6tjkUtxfB4GGe1eeQX7kjk1eXUmwQSad0xWE1Mbm2D1z9TXR+D9ILbZXWs7RbeK+uVaToK70yw6dY5AwFHYVKjdjbKHi/UUsNLMUZAduBWL4Ni/dPK33mNctreqyapqJJJ2A4UGu48MxiOzUe1D1YbI1rSQR3EqfQ1ck2yKQ2CDWRE4a/uf9kAVbE3ApiMzUbY2EhuYGIUckVK919ps1kB+8M1ZuAJ4mRuhrNiAjtWjHRCRSGRWU2zevvUjzjcKzVk2zn3p+4vJzQBoTN8me2K5DxFPwVFdTdOFt/wrhdWmDXOPek9gQmm2vnMGbgCtW7u4rWDZGRkVlPdfZ7JinDE4FY09w7nLMTUN8pW5ieOrgzS2rE8/N/SvQvCtz9o8O2Eh5PlAflxXlvi6TM8C+ik/ma7z4dzGTwzAuTlHZf1rOequbP4UdcrAjg/nTt2TVZXpwbmsyCcHikz+lRhyFOKTeTQI5vXFxqL+5zUmhQrP/aFvIMpKoB/Wpddt38w3AwU4B55FZttqMelWepahMQyxRg+WM7ic8c4x3rdRcvh3JvY4PxHpNzpWotHcq2wn5JP4XHYg/wBKqRgEAHpVzWviG+pK8M2lwNbMu3DOdwP94HsfwrOt5kkjSRDwwyMit+WUfiJunsaUMHy+taenxBJwxH3QSM1RsZBx61pBwFc/xFTTQjH1GUtKRu79DU2npkhgTUBgaaXc3IJrZs4PLUKAB70t2BbhUjBxmrh3KvbrUKo2QAfwNSSLsUs2c+vpVokZJKQu3Bz9a53UpC020/jWpfTgdCS3asC7ddxLZ3GhjIyQDwaahYEEA59M9agMwXHJyamgcq29Scdwe9SkBcGWAMv86vwlUQFRjHfFZX2pSMgEZ9KlScEMxJAHv1poRcDs2SZGBz2orPFwGydg60UXYXP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a commercially available upper arm functional brace being applied to immobilize a healing fracture of the shaft of the humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26486=[""].join("\n");
var outline_f25_55_26486=null;
var title_f25_55_26487="LV segmentation I";
var content_f25_55_26487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular segmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental analysis of LV walls based on schematic views, in a parasternal short-and long-axis orientation, at three different levels. The \"apex segments\" are usually visualized from apical 4-chamber, apical 2- and 3-chamber views. The apical cap can only be appreciated on some contrast studies. A 16-segment model can be used, without the apical cap, as described in an ASE 1989 document",
"    <sup>",
"     [1]",
"    </sup>",
"    . A 17-segment model, including the apical cap, has been suggested by the American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging",
"    <sup>",
"     [2]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2:358.",
"       </li>",
"       <li>",
"        Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation andnomenclature for tomographic imaging of the heart: a state-ment for healthcare professionals from the cardiac imagingcommittee of the council on clinical cardiology of the Amer-ican Heart Association. Circulation 2002; 105:539.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26487=[""].join("\n");
var outline_f25_55_26487=null;
var title_f25_55_26488="Small plaque parapsoriasis";
var content_f25_55_26488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small erythematous patches with fine scaling are characteristic of small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26488=[""].join("\n");
var outline_f25_55_26488=null;
var title_f25_55_26489="Causes and pathophysiology of Cushing's syndrome";
var content_f25_55_26489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and pathophysiology of Cushing's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26489/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/55/26489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Cushing's syndrome involves three steps: suspecting it on the basis of the patient's symptoms and signs, documenting the presence of hypercortisolism, and determining its cause. The last step requires an understanding of the classification and pathophysiology of the different types of Cushing's syndrome; these will be reviewed here. The clinical manifestations and diagnosis of Cushing's syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H503361\">",
"    <span class=\"h1\">",
"     PSEUDO-CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudo-Cushing&rsquo;s syndrome refers to physiologic hypercortisolism that can occur in several disorders other than Cushing's syndrome. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are physically stressed, such as by a severe bacterial infection",
"     </li>",
"     <li>",
"      Patients with severe obesity, especially those with visceral obesity or polycystic ovary syndrome",
"     </li>",
"     <li>",
"      Patients with malnutrition, anorexia nervosa or with intense chronic exercise",
"     </li>",
"     <li>",
"      Patients with psychological stress, especially patients with a severe major depressive disorder and melancholic symptoms",
"     </li>",
"     <li>",
"      Rarely, patients with chronic alcoholism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When such patients present with clinical features consistent with Cushing's syndrome, they may be referred to as having pseudo-Cushing's syndrome. However, the distinction is not always simple because patients with Cushing's syndrome can have serious infections, are frequently depressed (although it is often an atypical, agitated depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and presumably have a prevalence of chronic alcoholism similar to that of the general population.",
"   </p>",
"   <p>",
"    The psychiatric literature suggests that as many as 80 percent of patients with major depressive disorders have increased cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, cortisol hypersecretion, when present, is usually minimal. Furthermore, even severely depressed patients with substantial cortisol hypersecretion rarely develop clinical Cushing's syndrome. However, some depressed patients may be difficult to distinguish clinically or biochemically from those with Cushing's disease. Their abnormal cortisol secretion presumably results from hypothalamic-pituitary-adrenal axis hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/6\">",
"     6",
"    </a>",
"    ], and disappears after remission of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About three dozen patients with chronic alcoholism and clinical or biochemical manifestations of Cushing's syndrome have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Most had liver dysfunction, although the hormonal changes did not correlate closely with the degree of abnormality in liver function. In addition to liver dysfunction, these patients probably have transiently increased secretion of corticotropin-releasing hormone (CRH) or vasopressin, or impaired hypothalamic or pituitary responsiveness to cortisol. However, their peripheral and petrosal sinus plasma CRH concentrations are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/9\">",
"     9",
"    </a>",
"    ]. The hormonal abnormalities disappear rapidly during abstinence from alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's syndrome may be either corticotropin (ACTH)-dependent or -independent (",
"    <a class=\"graphic graphic_table graphicRef50582 \" href=\"UTD.htm?6/1/6172\">",
"     table 1",
"    </a>",
"    ). Among all patients presenting with Cushing&rsquo;s syndrome, the most common cause is iatrogenic Cushing&rsquo;s due to exogenous administration of glucocorticoids. The second most common form overall is Cushing&rsquo;s disease (pituitary hypersecretion of ACTH). (See",
"    <a class=\"local\" href=\"#H1083995823\">",
"     'Iatrogenic or factitious'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Cushing's disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ACTH-dependent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of ACTH-dependent Cushing's syndrome are associated with bilateral adrenocortical hyperplasia; their relative frequency is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cushing's disease (pituitary hypersecretion of ACTH) &mdash; 65 to 70 percent (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cushing's disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Ectopic secretion of ACTH by nonpituitary tumors &mdash; 10 to 15 percent (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Ectopic ACTH syndrome'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Ectopic secretion of corticotropin-releasing hormone (CRH) by nonhypothalamic tumors causing pituitary hypersecretion of ACTH &mdash; less than 1 percent (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Ectopic CRH syndrome'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Iatrogenic or factitious Cushing's syndrome due to administration of exogenous ACTH (not glucocorticoids) &mdash; less than 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ACTH-independent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of ACTH-independent Cushing's syndrome are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iatrogenic or factitious Cushing's syndrome, which is by far the most common cause as noted above (see",
"      <a class=\"local\" href=\"#H1083995823\">",
"       'Iatrogenic or factitious'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Adrenocortical adenomas and carcinomas &mdash; 18 to 20 percent (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary adrenocortical hyperfunction'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Primary pigmented nodular adrenocortical disease, also called bilateral adrenal micronodular hyperplasia &mdash; less than 1 percent (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary pigmented nodular adrenocortical disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Bilateral ACTH-independent macronodular hyperplasia &mdash; less than 1 percent; this disorder must be distinguished from macronodular hyperplasia in Cushing's disease in which plasma ACTH concentrations are not suppressed [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/10\">",
"       10",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Bilateral ACTH-independent macronodular hyperplasia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083995823\">",
"    <span class=\"h2\">",
"     Iatrogenic or factitious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic or factitious Cushing's syndrome is usually caused by administration of excessive amounts of a synthetic glucocorticoid and only rarely by ACTH administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common cause of hypercortisolism is ingestion of prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , usually for nonendocrine disease. However, Cushing's syndrome also can be caused by other oral, injected, topical, and inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/12-14\">",
"     12-14",
"    </a>",
"    ], and by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    or high dose medroxyprogesterone, progestins with some intrinsic glucocorticoid activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/15\">",
"     15",
"    </a>",
"    ]. The clearance of some inhaled steroids may be delayed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , leading to Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/16\">",
"     16",
"    </a>",
"    ]. Cushing's syndrome may also be caused by the use of glucocorticoid-containing creams or herbal preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factitious Cushing's syndrome is a rare disorder (responsible for less than one percent of patients with Cushing&rsquo;s syndrome) that refers to surreptitious intake of a glucocorticoid, often by patients who are close to the health professions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/11,19\">",
"     11,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACTH-DEPENDENT CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark biochemical feature of ACTH-dependent Cushing&rsquo;s syndrome is a normal or elevated ACTH level, which reflects tumoral secretion. The tumor secretion of ACTH causes bilateral adrenocortical hyperplasia and hyperfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/20\">",
"     20",
"    </a>",
"    ]. The increased serum cortisol concentrations inhibit both hypothalamic CRH and vasopressin secretion as well as ACTH secretion by normal pituitary corticotrophs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cushing's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with Cushing's disease have a pituitary adenoma, although the tumor is often not demonstrable by imaging; rare patients have diffuse corticotroph hyperplasia even in the absence of ectopic CRH secretion. The tumors are usually microadenomas; only about 5 to 10 percent are macroadenomas. The adenomas may overexpress the type 1 CRH receptors found in normal corticotrophs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/22\">",
"     22",
"    </a>",
"    ]. However, these receptors are unlikely to play a role in adenoma formation because CRH secretion is suppressed in patients with Cushing's disease. Patients with macroadenomas are more likely to have high plasma ACTH concentrations than are those with microadenomas (83 versus 45 percent), and the concentrations are less likely to fall with high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A smaller proportion of those with macroadenomas respond to CRH stimulation (65 versus 84 percent); however, in all of those features, there is considerable overlap between patients with microadenomas and macroadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACTH secretion in normal individuals, in patients with Cushing's disease, and in some patients with the ectopic ACTH syndrome respond to growth hormone-releasing peptide (GRP) or hexarelin stimulation; this is less frequent in patients with macroadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There are GRP receptors on corticotrophs, corticotroph adenoma cells, and nonpituitary neuroendocrine cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amplitude and duration, but not the frequency, of ACTH secretory episodes are increased in Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/28-33\">",
"     28-33",
"    </a>",
"    ], and the normal ACTH circadian rhythm is usually lost (",
"    <a class=\"graphic graphic_figure graphicRef54316 \" href=\"UTD.htm?14/2/14372\">",
"     figure 1",
"    </a>",
"    ). There is loss of tight synchrony between ACTH and cortisol secretory dynamics, perhaps reflecting the fact that ACTH secretion by the adenoma is not subject to hypothalamic regulation because of suppressed CRH, and is relatively resistant to direct glucocorticoid inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/34\">",
"     34",
"    </a>",
"    ]. The increased plasma ACTH concentrations, acting alone or in concert with other growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/35-38\">",
"     35-38",
"    </a>",
"    ], cause bilateral adrenocortical hyperplasia and hypersecretion of cortisol. Consequently, the normal circadian rhythm in cortisol secretion is also lost (",
"    <a class=\"graphic graphic_figure graphicRef60086 \" href=\"UTD.htm?2/18/2336\">",
"     figure 2",
"    </a>",
"    ). Morning plasma ACTH and serum cortisol concentrations may be normal, but late-evening concentrations are high. Salivary cortisol concentrations reflect those of serum free cortisol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .) The loss of the nocturnal nadir in serum and salivary cortisol is used to document the presence of Cushing&rsquo;s syndrome.",
"   </p>",
"   <p>",
"    The increased cortisol secretion is reflected by increased urinary excretion of cortisol and 17-OHCS. ACTH secretion is increased more than that of cortisol, suggesting that the adrenal cortex is relatively unresponsive to excess ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/33\">",
"     33",
"    </a>",
"    ]. ACTH receptor (MC2R) levels are relatively decreased in the adrenocortical hyperplasia tissues of Cushing&rsquo;s disease patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The relative activity of the enzymes involved in cortisol biosynthesis does not change and, therefore, the production and excretion of cortisol precursors are increased proportionately.",
"   </p>",
"   <p>",
"    The corticotroph adenoma cells respond to decreases in serum cortisol concentrations by increasing ACTH secretion and to increases in serum cortisol concentrations (or other glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) by decreasing ACTH secretion, but quantitatively the cells are relatively resistant to negative feedback inhibition by glucocorticoids. In effect, the tumor cells function at a higher than normal set point for cortisol feedback inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/3\">",
"     3",
"    </a>",
"    ]. This characteristic is clinically important because it permits the use of dexamethasone suppression to distinguish between pituitary and ectopic ACTH secretion; the latter is usually very resistant to glucocorticoid negative feedback. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"     \"Dexamethasone suppression tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism for the resistance of corticotroph adenoma cells to glucocorticoid negative feedback inhibition is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resistance to glucocorticoids may, in some cases, reflect abnormalities in the glucocorticoid receptor. In one report, a somatic frame-shift mutation of the glucocorticoid type 2 receptor was found in the tumor in one of four patients with Nelson's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/41\">",
"       41",
"      </a>",
"      ]. In another study, the tumors of 6 of 22 patients with Cushing's disease showed loss of heterozygosity for one of five polymorphisms at the glucocorticoid receptor type 1 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/42\">",
"       42",
"      </a>",
"      ]. Loss of heterozygosity was not detected in other types of pituitary adenomas.",
"     </li>",
"     <li>",
"      Abnormal expression of 11-beta-hydroxysteroid dehydrogenase isoenzyme 2 (11-beta-HSD-2; which converts cortisol to cortisone) in ACTH-secreting adenoma cells is a second possible mechanism for insensitivity to glucocorticoid feedback [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found deficient nuclear expression of one or two proteins, Brg1 and histone deacetylase 2 (HDAC2), in 17 of 36 human corticotroph adenomas. Decreased nuclear localization of these proteins, which are involved in repression of the POMC gene, may account for resistance to glucocorticoid feedback in a subset of patients with Cushing's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The corticotroph adenomas that occur in about 2 percent of patients with multiple endocrine neoplasia type 1 (MEN 1) syndrome occur at the same age, but tend to be larger and more resistant to glucocorticoid negative feedback than sporadic corticotroph adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the adrenal glands become increasingly hyperplastic, they secrete proportionately more cortisol in response to a given increment in plasma ACTH. This response serves to restrain ACTH secretion, even to the point of \"autosuppression.\" This phenomenon is especially pronounced in patients with severe bilateral macronodular adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/47-51\">",
"     47-51",
"    </a>",
"    ], in whom plasma ACTH concentrations may not exceed 15",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    Such patients may be thought erroneously to have ACTH-independent Cushing's syndrome, but their ACTH levels can increase following administration of CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/52\">",
"     52",
"    </a>",
"    ]. However, no case of Cushing's disease has been documented to progress to fully ACTH-independent Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ectopic ACTH syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except in some patients with benign neuroendocrine (&lsquo;&lsquo;carcinoid&rsquo;&rsquo;) tumors, usually bronchial in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], ACTH secretion from malignant ectopic sources such as from oat-cell carcinoma is not inhibited by cortisol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or other glucocorticoids. In rare patients, glucocorticoids increase tumor secretion of ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/56\">",
"     56",
"    </a>",
"    ]. In general, tumors causing the ectopic ACTH syndrome tend to secrete a disproportionately greater proportion of POMC precursors, and these may be their major product. As in Cushing's disease, salivary cortisol concentrations reflect those of serum free cortisol and urinary excretion of cortisol and its precursors is increased proportionately.",
"   </p>",
"   <p>",
"    Tumors of a wide variety of tissues, usually carcinomas rather than sarcomas or lymphomas, have been associated with the ectopic ACTH syndrome; however, Ewing&rsquo;s sarcoma has been reported in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/57\">",
"     57",
"    </a>",
"    ]. Most cases are caused by tumors of the lung, pancreas, or thymus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/20,58,59\">",
"     20,58,59",
"    </a>",
"    ]. Among them the most common are small-cell carcinomas of the lung that, like pulmonary carcinoids and rare multiple pulmonary tumorlets, arise from neuroendocrine cells in the distal bronchioles [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/60\">",
"     60",
"    </a>",
"    ]. The ACTH-secreting pancreatic and thymic tumors are also carcinoid tumors that arise from neuroendocrine cells in those tissues.",
"   </p>",
"   <p>",
"    Inappropriate repression or expression of certain genes, presumably similar to those in normal pituitary corticotropes, causes these tumors to secrete ACTH and other POMC-derived peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ectopic CRH syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ectopic CRH syndrome, CRH secretion by the tumor causes hyperplasia and hypersecretion of the pituitary corticotrophs, resulting sequentially in ACTH hypersecretion, cortisol hypersecretion, and bilateral adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/62\">",
"     62",
"    </a>",
"    ]. In some of these patients, pituitary ACTH secretion can be inhibited by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/62\">",
"     62",
"    </a>",
"    ]. However, many of these tumors also secrete ACTH, which is not inhibited by dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/63-67\">",
"     63-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting variant of this syndrome was caused by a CRH-secreting gangliocytoma composed of hypothalamic-like neurons within the sella turcica, adjacent to the pituitary gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/68\">",
"     68",
"    </a>",
"    ]. There was partial (ie, 40 percent) suppression of cortisol secretion with a low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ; the high-dose test was not performed. There was also a fourfold increase in urinary 17-OHCS excretion in response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , further indicating that ACTH secretion was responsive to glucocorticoid negative feedback regulation. The patient recovered normal hypothalamic-pituitary-adrenal function after removal of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ACTH-INDEPENDENT CUSHING'S SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary adrenocortical hyperfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Cushing's syndrome due to primary adrenocortical disease (eg, adrenocortical tumor, micronodular dysplasia, or ACTH-independent macronodular hyperplasia), increased cortisol secretion suppresses both CRH and ACTH secretion, as it does in normal subjects. The normal pituitary corticotrophs atrophy, as do the normal zonae fasciculata and reticularis of the adrenal glands.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenal adenomas that cause Cushing's syndrome produce cortisol very efficiently. As ACTH is suppressed, serum dehydroepiandrosterone (DHEA-S) concentrations and urinary excretion of DHEA-S are usually low relative to urinary cortisol excretion, or may be normal. However, occasional adrenal adenomas produce relatively large amounts of androgen due to an increase in the 17, 20-lyase activity of CYP17 (P450c17, 17-alpha-hydroxylase) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/69\">",
"       69",
"      </a>",
"      ]. Levels of CYP21A2 (P450c21, 21-hydroxylase), CYP17, and CYP11A1 (P450scc, cholesterol side-chain cleavage enzyme, cholesterol desmolase) mRNA are normal in cortisol-producing adenomas and 60 to 80 percent of normal in carcinomas, roughly proportional to their steroidogenic activities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, adrenal carcinomas are frequently inefficient in terms of steroidogenesis. Since the efficiency per cell in converting cholesterol to cortisol is low, but cell mass is very large, their production of cortisol precursors (eg, urinary 17-KS and serum and urinary DHEA-S) is disproportionately higher. Even in patients with adrenal carcinomas who presumably do not produce excess steroids, more sensitive methods such as gas",
"      <span class=\"nowrap\">",
"       chromatography/mass",
"      </span>",
"      spectrometry identify increased urinary metabolites of several steroids and precursors of androgens (pregnenediol, pregnenetriol, androsterone, etiocholanolone) or glucocorticoids (17-hydroxyproesterone, tetrahydro-11-deoxycortisol, cortisol, 6-hydroxy cortisol, tetrahydrocortisol, and &alpha;-cortol) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low serum aldosterone concentrations but normal or high serum or urinary concentrations of aldosterone precursors (ie, deoxycorticosterone, 18-hydroxydeoxycorticosterone, corticosterone, and 18-hydroxycorticosterone, tetrahydro-11-deoxycorticosterone [THDOC and 5-&alpha; THDOC]) are found in most adrenal carcinomas but not in adrenal adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most adrenocortical tumors are monoclonal, suggesting that they result from accumulated genetic abnormalities such as activation of protooncogenes and inactivation of tumor suppressor genes. The association of adrenal cancer with familial syndromes suggests specific gene abnormalities (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Li-Fraumeni syndrome is caused by abnormalities in TP53, a tumor suppressor gene. An inherited mutation of the gene was found in cases of pediatric adrenal cancer in Brazil [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/73\">",
"       73",
"      </a>",
"      ]. In another study, the gene was abnormal in 5 of 20 adults with adrenal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The association of Beckwith-Wiedemann syndrome with adrenal cancer implicates IGF-II in the disorder. In one study, loss of heterozygosity in 11p15, which includes the IGFII gene, or overexpression of the gene, was demonstrated in 27 of 29 of sporadic malignant tumors and 3 of 35 benign tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A high proportion of adrenal tumors, mostly adenomas, causing Cushing's syndrome have receptors for and are responsive to agonists such as gastric inhibitory polypeptide (GIP), vasopressin, beta-adrenergic agents, serotonin, luteinizing",
"      <span class=\"nowrap\">",
"       hormone/chorionic",
"      </span>",
"      gonadotropin, and perhaps leptin or interleukin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/10\">",
"       10",
"      </a>",
"      ]. In addition, rare pure androgen-secreting tumors respond to luteinizing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/10,76\">",
"       10,76",
"      </a>",
"      ]. Approximately 50 percent of the adenomas also respond to ACTH by increasing cortisol production, presumably because they have normal ACTH (melanocortin-2) receptors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary pigmented nodular adrenocortical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are both sporadic and familial forms of primary pigmented nodular adrenocortical disease, also called bilateral adrenal micronodular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/77\">",
"     77",
"    </a>",
"    ]. The familial form, Carney syndrome or complex, is an autosomal dominant disorder characterized by two major types of findings: pigmented lentigines and blue nevi on the face, neck, and trunk, including the lips, conjunctivae, and sclerae; and multiple neoplasms, both endocrine (testicular Sertoli cells and occasionally adrenal, pituitary, or thyroid) and nonendocrine (cutaneous, mammary, atrial myxomas, and psammomatous melanotic schwannomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H20#H20\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Sex cord-stromal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bilateral ACTH-independent macronodular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome is associated with adrenal glands that weigh from 24 to 500 g or more and contain multiple nonpigmented nodules greater than 5 mm in diameter. The nodules appear to be typical benign adrenal nodules, but the internodular cortex may be hypertrophic, rather than atrophic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of bilateral macronodular hyperplasia appears to involve overexpression of eutopic receptors, inappropriate expression of ectopic receptors, or coupling of eutopic receptors to steroidogenic signaling pathways; in the majority of patients, increases in cortisol secretion are mediated by overexpression of receptors for either vasopressin, serotonin, beta-adrenergic agonists, luteinizing",
"    <span class=\"nowrap\">",
"     hormone/chorionic",
"    </span>",
"    gonadotropin, gastric inhibitory polypeptide or perhaps glucagon or leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most initial cases of AIMAH appeared to be sporadic. There are now several reports of familial cases of AIMAH whose presentation suggests autosomal dominant transmission. In familial cases, a number of aberrant hormone receptors have been identified in individual families, including V1-V2- and V3-vasopressin, beta-adrenergic, combined V1-vasopressin and beta-adrenergic, and combined 5HT4 and V1-V-2 vasopressin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are occasional reports that are difficult to reconcile with current understanding of the pathophysiology of ACTH-independent primary adrenal disease. As an example, adrenal adenomas have been described in association with bilateral nodular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/79\">",
"     79",
"    </a>",
"    ], as has nonpigmented bilateral micronodular hyperplasia thought to have resulted from longstanding Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/80\">",
"     80",
"    </a>",
"    ]. A woman with virilization but no stigmata of Cushing's syndrome was found to have bilateral macronodular adrenal hyperplasia with overexpression of luteinizing",
"    <span class=\"nowrap\">",
"     hormone/chorionic",
"    </span>",
"    gonadotropin receptors and excessive adrenal testosterone production [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/81\">",
"     81",
"    </a>",
"    ]. Her serum testosterone levels were increased, but her serum cortisol concentrations were normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Iatrogenic or factitious Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic or factitious Cushing's syndrome is usually caused by administration of excessive amounts of a synthetic glucocorticoid or compounds such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , which have some intrinsic glucocorticoid activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/15\">",
"     15",
"    </a>",
"    ]. Exogenous glucocorticoids inhibit CRH and ACTH secretion, causing bilateral adrenocortical atrophy. Plasma ACTH, serum and salivary cortisol concentrations, and urinary cortisol excretion (unless cortisol is the steroid administered) are all low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link&amp;anchor=H5#H5\">",
"     \"Establishing the diagnosis of Cushing's syndrome\", section on 'Does the patient have Cushing's syndrome?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ectopic cortisol secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of ectopic cortisol production from ovarian tumors that led to ACTH-independent CS have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Normocortisolemic Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patients have been described who had signs of Cushing's syndrome, but had normal or low cortisol secretion. One was a 54-year-old man with centripetal obesity, moon facies, and type 2 diabetes but no other clinical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/83\">",
"     83",
"    </a>",
"    ]. He had low serum cortisol and undetectable plasma ACTH concentrations and failed to respond normally to the short ACTH, insulin-induced hypoglycemia, CRH-plus-vasopressin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation tests. Cortisol secretion increased markedly in response to a two-day ACTH stimulation test. These findings are typical of administration of exogenous synthetic glucocorticoid, which was excluded by prolonged observation. The investigators concluded that there was increased tissue sensitivity to cortisol and demonstrated increased induction of a glucocorticoid-responsive gene in the patient's fibroblasts by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other patient was a 10-year-old girl with centripetal obesity, moon facies, purple striae, osteopenia, vertebral compression fractures, and amenorrhea but normal linear growth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/85\">",
"     85",
"    </a>",
"    ]. Her plasma ACTH concentrations were normal and, although she appeared on occasion to have an abnormal diurnal rhythm in serum cortisol, urinary cortisol excretion was always normal, excluding hypercortisolism. She had a variable increase in type 2 corticosteroid (glucocorticoid) receptor numbers in her peripheral lymphocytes, but these did not correlate with her clinical course. The receptor gene and its promoter usage were normal. Her condition improved when she took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    but did not worsen when it was discontinued after 21 months at age 15.5 years. The pathogenesis of this forme fruste of Cushing's syndrome is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574417\">",
"    <span class=\"h2\">",
"     Biochemical hypercortisolism without Cushingoid features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patients with clear-cut moderate to severe hypercortisolism but absent clinical features have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26489/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Each had impaired cortisone to cortisol conversion in vivo and decreased cortisol:cortisone metabolites, consistent with impaired 11-beta hydroxysteroid dehydrogenase type I activity. Increased cortisol clearance was postulated as the mechanism by which the patients were protected from tissue actions of cortisol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       \"Patient information: Cushing's syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=see_link\">",
"       \"Patient information: Cushing's syndrome treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083996610\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cushing's syndrome may be either corticotropin (ACTH)-dependent or -independent (",
"      <a class=\"graphic graphic_table graphicRef50582 \" href=\"UTD.htm?6/1/6172\">",
"       table 1",
"      </a>",
"      ). Among all patients presenting with Cushing&rsquo;s syndrome, the most common cause is iatrogenic Cushing&rsquo;s due to exogenous administration of glucocorticoids. The second most common form overall is Cushing&rsquo;s disease (pituitary hypersecretion of ACTH).",
"     </li>",
"     <li>",
"      The causes of ACTH-dependent Cushing's syndrome are associated with bilateral adrenocortical hyperplasia. Their relative frequency is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cushing's disease (pituitary hypersecretion of ACTH) &mdash; 65 to 70 percent (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cushing's disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ectopic secretion of ACTH by nonpituitary tumors &mdash; 10 to 15 percent (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Ectopic ACTH syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ectopic secretion of corticotropin-releasing hormone (CRH) by nonhypothalamic tumors causing pituitary hypersecretion of ACTH &mdash; less than 1 percent (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Ectopic CRH syndrome'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes and frequencies of ACTH-independent Cushing's syndrome are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Iatrogenic or factitious Cushing's syndrome (see",
"      <a class=\"local\" href=\"#H1083995823\">",
"       'Iatrogenic or factitious'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Adrenocortical adenomas and carcinomas &mdash; 18 to 20 percent (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary adrenocortical hyperfunction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary pigmented nodular adrenocortical disease, also called bilateral adrenal micronodular hyperplasia &mdash; less than 1 percent (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary pigmented nodular adrenocortical disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Bilateral ACTH-independent macronodular hyperplasia &mdash; less than 1 percent (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Bilateral ACTH-independent macronodular hyperplasia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudo-Cushing&rsquo;s syndrome refers to physiologic hypercortisolism that can occur in several disorders other than Cushing's syndrome. Examples include severe obesity, depression, chronic strenuous activity, and alcoholism. (See",
"      <a class=\"local\" href=\"#H503361\">",
"       'Pseudo-Cushing's syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/1\">",
"      Kirkman S, Nelson DH. Alcohol-induced pseudo-Cushing's disease: a study of prevalence with review of the literature. Metabolism 1988; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/2\">",
"      Groote Veldman R, Meinders AE. On the mechanism of alcohol-induced pseudo-Cushing's syndrome. Endocr Rev 1996; 17:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/3\">",
"      LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/4\">",
"      Loosen PT, Chambliss B, DeBold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/5\">",
"      Pfohl B, Sherman B, Schlechte J, Winokur G. Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol Psychiatry 1985; 20:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/6\">",
"      Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/7\">",
"      Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/8\">",
"      Amsterdam JD, Maislin G, Winokur A, et al. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 1988; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/9\">",
"      Yanovski JA, Nieman LK, Doppman JL, et al. Plasma levels of corticotropin-releasing hormone in the inferior petrosal sinuses of healthy volunteers, patients with Cushing's syndrome, and patients with pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/10\">",
"      Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/11\">",
"      Quddusi S, Browne P, Toivola B, Hirsch IB. Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med 1998; 158:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/12\">",
"      Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/13\">",
"      Nutting CM, Page SR. Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at! Postgrad Med J 1995; 71:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/14\">",
"      Hughes JM, Hichens M, Booze GW, Thorner MO. Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate. Arch Intern Med 1986; 146:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/15\">",
"      Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/16\">",
"      Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/17\">",
"      Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/18\">",
"      Oldenburg-Ligtenberg PC, van der Westerlaken MM. A woman with Cushing's syndrome after use of an Indonesian herb: a case report. Neth J Med 2007; 65:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/19\">",
"      Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.",
"     </a>",
"    </li>",
"    <li>",
"     Orth DN. Ectopic hormone production. In: Endocrinology and metabolism, 2nd, Felig P, Baxter JD, Broadus AE, Frohman LA (Eds), McGraw-Hill, New York 1987. p.1692.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/21\">",
"      Kling MA, Roy A, Doran AR, et al. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab 1991; 72:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/22\">",
"      Dieterich KD, Gundelfinger ED, L&uuml;decke DK, Lehnert H. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1998; 83:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/23\">",
"      Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998; 83:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/24\">",
"      Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/25\">",
"      Arvat E, Giordano R, Ramunni J, et al. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. J Clin Endocrinol Metab 1998; 83:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/26\">",
"      Jansson JO, Svensson J, Bengtsson BA, et al. Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 1998; 48:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/27\">",
"      de Keyzer Y, Lenne F, Bertagna X. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol 1997; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/28\">",
"      Hellman L, Weitzman ED, Roffwarg H, et al. Cortisol is secreted episodically in Cushing's syndrome. J Clin Endocrinol Metab 1970; 30:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/29\">",
"      Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology. J Clin Endocrinol Metab 1973; 36:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/30\">",
"      Boyar RM, Witkin M, Carruth A, Ramsey J. Circadian cortisol secretory rhythms in Cushing's disease. J Clin Endocrinol Metab 1979; 48:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/31\">",
"      Liu JH, Kazer RR, Rasmussen DD. Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing's disease. J Clin Endocrinol Metab 1987; 64:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/32\">",
"      Stewart PM, Penn R, Gibson R, et al. Hypothalamic abnormalities in patients with pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/33\">",
"      van den Berg G, Fr&ouml;lich M, Veldhuis JD, Roelfsema F. Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands. J Clin Endocrinol Metab 1995; 80:3750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/34\">",
"      Roelfsema F, Pincus SM, Veldhuis JD. Patients with Cushing's disease secrete adrenocorticotropin and cortisol jointly more asynchronously than healthy subjects. J Clin Endocrinol Metab 1998; 83:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/35\">",
"      LIDDLE GW, ISLAND D, RINFRET AP, FORSHAM PH. Factors enhancing the response of the human adrenal to corticotropin. Is there an adrenal growth factor? J Clin Endocrinol Metab 1954; 14:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/36\">",
"      Segal BM, Drucker WD, Benovitz H, et al. Further studies of adrenal weight-maintaining activity in the plasma of patients with Cushing's disease. Am J Med 1970; 49:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/37\">",
"      Hornsby PJ, Sturek M, Harris SE, Simonian MH. Serum and growth factor requirements for proliferation of human adrenocortical cells in culture: comparison with bovine adrenocortical cells. In Vitro 1983; 19:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/38\">",
"      Estivariz FE, Morano MI, Carino M, et al. Adrenal regeneration in the rat is mediated by mitogenic N-terminal pro-opiomelanocortin peptides generated by changes in precursor processing in the anterior pituitary. J Endocrinol 1988; 116:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/39\">",
"      Reincke M, Beuschlein F, Latronico AC, et al. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clin Endocrinol (Oxf) 1997; 46:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/40\">",
"      Antonini SR, Baldacchino V, Tremblay J, et al. Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2006; 64:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/41\">",
"      Karl M, Von Wichert G, Kempter E, et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996; 81:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/42\">",
"      Huizenga NA, de Lange P, Koper JW, et al. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab 1998; 83:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/43\">",
"      Korbonits M, Bujalska I, Shimojo M, et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J Clin Endocrinol Metab 2001; 86:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/44\">",
"      Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/45\">",
"      Verg&egrave;s B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/46\">",
"      Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/47\">",
"      Choi Y, Werk EE Jr, Sholiton LJ. Cushing's syndrome with dual pituitary-adrenal control. Arch Intern Med 1970; 125:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/48\">",
"      Burke, CW. Disorders of cortisol production: diagnostic and therapeutic progress. Recent Adv Endocrinol Metab 1978; 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/49\">",
"      Aron DC, Findling JW, Fitzgerald PA, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/50\">",
"      Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/51\">",
"      Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985; 14:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/52\">",
"      Hermus AR, Pieters GF, Smals AG, et al. Transition from pituitary-dependent to adrenal-dependent Cushing's syndrome. N Engl J Med 1988; 318:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/53\">",
"      Strott CA, Nugent CA, Tyler FH. Cushing's syndrome caused by bronchial adenomas. Am J Med 1968; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/54\">",
"      Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/55\">",
"      de Keyzer Y, Lenne F, Auzan C, et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996; 97:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/56\">",
"      White A, Ray DW, Talbot A, et al. Cushing's syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:4771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/57\">",
"      More J, Young J, Reznik Y, et al. Ectopic ACTH syndrome in children and adolescents. J Clin Endocrinol Metab 2011; 96:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/58\">",
"      Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/59\">",
"      Neary NM, Lopez-Chavez A, Abel BS, et al. Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. J Clin Endocrinol Metab 2012; 97:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/60\">",
"      Arioglu E, Doppman J, Gomes M, et al. Cushing's syndrome caused by corticotropin secretion by pulmonary tumorlets. N Engl J Med 1998; 339:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/61\">",
"      Pascual-Le Tallec L, Dulmet E, Bertagna X, de Keyzer Y. Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors. J Clin Endocrinol Metab 2002; 87:5015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/62\">",
"      Carey RM, Varma SK, Drake CR Jr, et al. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N Engl J Med 1984; 311:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/63\">",
"      Schteingart DE, Lloyd RV, Akil H, et al. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 1986; 63:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/64\">",
"      Zorate, A, Kovacs, K, Flores, M, et al. ACTH and CRF-producing bronchial carcinoid associated with Cushing's syndrome. Clin Endocrinol 1986; 24:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/65\">",
"      Jessop DS, Cunnah D, Millar JG, et al. A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol 1987; 113:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/66\">",
"      O'Brien T, Young WF Jr, Davila DG, et al. Cushing's syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma. Clin Endocrinol (Oxf) 1992; 37:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/67\">",
"      Orth DN. Corticotropin-releasing hormone in humans. Endocr Rev 1992; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/68\">",
"      Asa SL, Kovacs K, Tindall GT, et al. Cushing's disease associated with an intrasellar gangliocytoma producing corticotrophin-releasing factor. Ann Intern Med 1984; 101:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/69\">",
"      Sakai Y, Yanase T, Takayanagi R, et al. High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgens. J Clin Endocrinol Metab 1993; 76:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/70\">",
"      Beuschlein F, Schulze E, Mora P, et al. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. J Clin Endocrinol Metab 1998; 83:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/71\">",
"      Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/72\">",
"      Aupetit-Faisant B, Battaglia C, Zenatti M, et al. Hypoaldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: a marker of adrenal carcinoma. J Clin Endocrinol Metab 1993; 76:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/73\">",
"      Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 2006; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/74\">",
"      Sidhu S, Martin E, Gicquel C, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 2005; 31:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/75\">",
"      Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997; 82:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/76\">",
"      Lacroix A, Bourdeau I, Lampron A, et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2010; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/77\">",
"      Larsen JL, Cathey WJ, Odell WD. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome. Case report and review of the literature. Am J Med 1986; 80:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/78\">",
"      Carney, JA, Young, WF Jr. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 1992; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/79\">",
"      Hocher B, B&auml;hr V, Dorfm&uuml;ller S, Oelkers W. Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: transition from pituitary-dependent to adrenal-dependent Cushing's syndrome. Acta Endocrinol (Copenh) 1993; 128:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/80\">",
"      Iino K, Sasano H, Nagura H, et al. Adrenal adenoma with bilateral adrenocortical nodular change in a patient with Cushing's syndrome. Clin Endocrinol (Oxf) 1997; 47:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/81\">",
"      Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/82\">",
"      Marieb NJ, Spangler S, Kashgarian M, et al. Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J Clin Endocrinol Metab 1983; 57:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/83\">",
"      Iida S, Nakamura Y, Fujii H, et al. A patient with hypocortisolism and Cushing's syndrome-like manifestations: cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1990; 70:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/84\">",
"      Fujii H, Iida S, Gomi M, et al. Augmented induction by dexamethasone of metallothionein IIa messenger ribonucleic acid in fibroblasts from a patient with cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1993; 76:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/85\">",
"      Newfield RS, Kalaitzoglou G, Licholai T, et al. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers. J Clin Endocrinol Metab 2000; 85:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/86\">",
"      Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26489/abstract/87\">",
"      Arai H, Kobayashi N, Nakatsuru Y, et al. A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity. Endocr J 2008; 55:709.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 125 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26489=[""].join("\n");
var outline_f25_55_26489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1083996610\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H503361\">",
"      PSEUDO-CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACTH-dependent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACTH-independent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1083995823\">",
"      Iatrogenic or factitious",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACTH-DEPENDENT CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cushing's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ectopic ACTH syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ectopic CRH syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACTH-INDEPENDENT CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary adrenocortical hyperfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bilateral ACTH-independent macronodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Iatrogenic or factitious Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ectopic cortisol secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Normocortisolemic Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H574417\">",
"      Biochemical hypercortisolism without Cushingoid features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1083996610\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/125|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/2/14372\" title=\"figure 1\">",
"      ACTH Cushings disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/18/2336\" title=\"figure 2\">",
"      Episodic cortisol in Cushings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/1/6172\" title=\"table 1\">",
"      Causes of Cushings syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=related_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=related_link\">",
"      Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_55_26490="Evaluation of the potential renal transplant recipient";
var content_f25_55_26490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the potential renal transplant recipient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Emilio Ramos, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/55/26490/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/55/26490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney transplantation is the treatment of choice for end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis. There is, however, a shortage of donated organs and a growing wait list for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result patients are waiting longer to receive a kidney transplant and there are an increasing number of older patients with more comorbidities on the waitlist.",
"   </p>",
"   <p>",
"    Because of the relative scarcity of donor kidneys and prevalence of older and potentially sicker patients on the wait list, it is important that potential kidney transplant recipients are carefully evaluated in order to detect and treat coexisting illnesses which may affect transplant candidacy, perioperative risk, and survival after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .) The evaluation should be as efficient and cost-effective as possible.",
"   </p>",
"   <p>",
"    This topic will review the evaluation of a potential renal transplant recipient. The evaluation of the renal transplant donor is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to patient survival following transplantation, risk factors associated with graft failure, and the kidney transplant waiting list are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255110068\">",
"    <span class=\"h1\">",
"     TIMING OF TRANSPLANTATION REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little reliable information concerning the ability to predict the rate of progression of renal failure among patients with a variety of underlying renal diseases. Patients not yet requiring dialysis should not undergo renal transplantation until renal function has irreversibly deteriorated beyond a threshold level of clearance. This absolute level remains unclear, but should represent a degree of renal function not associated with signs or symptoms of uremia.",
"   </p>",
"   <p>",
"    Transplantation should be discussed with all patients with irreversible and progressive chronic kidney disease. Patients who are interested in transplantation and who have no known contraindications should be referred to a transplantation program when the estimated GFR (glomerular filtration rate) is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with a potential contraindication to transplantation should be individually discussed with a transplant center to determine candidacy.",
"   </p>",
"   <p>",
"    The 2005 Canadian Society of Transplantation consensus guidelines suggest that transplantation should not be performed unless the GFR is less than 20",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    and there is evidence of progressive irreversible deterioration over a period of 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef54575 \" href=\"UTD.htm?6/47/6909\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"     6",
"    </a>",
"    ]. An exception may be in cases in which the combination of kidney and nonrenal solid organ transplantation is being considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=see_link\">",
"     \"Renal function and nonrenal solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, candidates can be placed on and accrue wait-time on the deceased donor wait list when GFR is 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or less or when they are receiving chronic dialysis therapy.",
"   </p>",
"   <p>",
"    Several studies have reported improved patient and graft survival when patients receive their first transplant before the need for maintenance dialysis, although this is not the case for patients who are receiving a second transplant; among the latter, a period of dialysis prior to retransplantation is associated with better patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL DATA COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of the potential recipient should include a thorough medical, surgical and psychosocial history, and a detailed physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. Potential sensitization risks should be evaluated including history of blood or platelet transfusion, pregnancies, and previous transplants. Special attention is directed at the cardiopulmonary exam, dentition and peripheral arterial pulses. A careful examination of the abdomen for previous abdominal operations is also important [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood type, complete blood count, blood urea nitrogen, creatinine, electrolytes, calcium, phosphorous, albumin, liver function tests, prothrombin time, and partial thromboplastin time, fasting lipid panel, uric acid, and parathyroid hormone level.",
"     </li>",
"     <li>",
"      A pregnancy test for potentially fertile women.",
"     </li>",
"     <li>",
"      Serologic testing for HIV, cytomegalovirus, varicella virus, herpes simplex virus, Epstein Barr virus, hepatitis virus A, B, and C, and RPR. Some, but not all, centers also measure toxoplasmosis, coccidioidomycosis, chagas, and histoplasmosis titers in patients from endemic areas.",
"     </li>",
"     <li>",
"      HLA typing and a panel reactive antibody assay to detect for previous sensitization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"       \"HLA matching and graft survival in kidney transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"       \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinalysis.",
"     </li>",
"     <li>",
"      PPD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest x-ray. Given the poor sensitivity of the PPD in dialysis patients, the newer interferon-gamma release assays may be used among patients from endemic areas, those who have had exposure to tuberculosis, and if PPD or CXR are abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest x-ray and electrocardiogram. Depending upon age and comorbidities, echocardiography, thallium myocardium perfusion scan,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography, or catheterization may also be done.",
"     </li>",
"     <li>",
"      All men should have a careful testicular examination. Although the use of the prostate specific antigen (PSA) is increasingly controversial, men over 50 years of age should have measurement of PSA and a digital rectal examination. Black men and men with a family history of prostate cancer should have a PSA measurement and a rectal examination starting at age 40.",
"     </li>",
"     <li>",
"      All women should have a careful breast examination and Papanicolaou smear. Women over the age of 40 should have mammography; the age for mammography should be lowered to 35 if there is a history of breast cancer in the premenopausal years in a first-degree relative.",
"     </li>",
"     <li>",
"      All patients over the age of 50 should have screening colonoscopy. Patients who have a history of Barrett&rsquo;s esophagus should also have esophagogastroduodenoscopy (EGD).",
"     </li>",
"     <li>",
"      Abdominal and pelvic ultrasounds are done to image kidneys and ureters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the above information is gathered and there are no contraindications to transplantation, a meeting is arranged with the patient and his or her family, the transplant surgeon, the transplant nephrologist, and the transplant coordinator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few generally accepted contraindications to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Untreated current infection.",
"     </li>",
"     <li>",
"      Active malignancy with short life expectancy.",
"     </li>",
"     <li>",
"      Chronic illness with shortened life expectancy: there is no universally accepted life expectancy below which an individual is ineligible for renal transplantation, although a life expectancy of less than one year precludes the possibility of transplantation at virtually all centers. Some centers are hesitant to transplant an individual with a life expectancy of less than five years since that is generally the expected half life of the allograft. However, in other centers, individuals with much shorter life expectancy may be eligible for transplantation, depending upon the nature of the chronic illness.",
"     </li>",
"     <li>",
"      Active substance abuse.",
"     </li>",
"     <li>",
"      Reversible renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications, which require careful evaluation and possible prior therapy as described below, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active infection",
"     </li>",
"     <li>",
"      Advanced or uncorrectable coronary artery disease or congestive heart failure",
"     </li>",
"     <li>",
"      Active hepatitis or chronic liver disease",
"     </li>",
"     <li>",
"      Severe peripheral vascular disease, claudication",
"     </li>",
"     <li>",
"      Active peptic ulcer disease",
"     </li>",
"     <li>",
"      Cerebrovascular disease",
"     </li>",
"     <li>",
"      Proven habitual medical noncompliance or insurmountable psychosocial barriers to post-transplant compliance.",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      History of cancer (excluding basal cell skin cancer)",
"     </li>",
"     <li>",
"      HIV infection. Most centers exclude patients who test positive for HIV. In selected cases, patients should be eligible for solid organ transplantation if they CD4+ T-cell counts at least 200 per cubic millimeter and undetectable plasma viral load, which is the selection criteria in the HIV kidney transplant population reported in the HIV-infection center experience protocol [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/15\">",
"       15",
"      </a>",
"      ]. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"       \"Solid organ transplantation in HIV-infected individuals\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary oxalosis is a relative contraindication to single organ kidney donation: such patients should be evaluated for combined kidney-liver transplantation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link&amp;anchor=H58182972#H58182972\">",
"       \"Primary hyperoxaluria\", section on 'Transplantation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe hyperparathyroidism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advanced age, prior transplantation and specific renal diagnosis are not contraindications to transplantation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Is age a contraindication?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with end-stage renal disease (ESRD) and other end-stage organ failure may be candidates for combined organ transplantation (eg, liver-kidney transplantation if concurrent ESRD and end-stage liver failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Is age a contraindication?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipient age alone should no longer be considered a contraindication to transplantation, since the age limit for being a transplant recipient has steadily increased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Many patients over the age of 60, and selected patients over 70, have been transplanted safely and with an acceptable rate of long-term graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In the 2008 Scientific Registry of Transplant Recipients report, recipients of deceased non-expanded criteria donor kidneys who were 65 years and older constituted 13 percent of the total pool in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/17\">",
"     17",
"    </a>",
"    ]. However, patients should have an estimated life expectancy exceeding the anticipated wait time and kidney transplantation should not be pursued in cases where limited life expectancy minimizes the potential benefit of transplant.",
"   </p>",
"   <p>",
"    Elderly patients are also candidates for expanded-criteria donor kidneys. Use of an expanded-criteria donor kidney is particularly appropriate for older individuals without a living donor as such patients may have a prolonged wait for a standard criteria donor kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=see_link\">",
"     \"Renal transplantation and the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427613\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of issues should be considered before making a final decision as to the acceptability of a patient for renal transplantation. These include specific and relative contraindications as well as other issues which may require resolution prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prior transplant course including complications, cause of graft loss, and any history of noncompliance should be obtained. Most centers retransplant suitable candidates, although second and later transplants are associated with a higher rate of graft failure. The majority of centers do not require a minimum waiting time prior to the next transplant; however, those patients who are highly sensitized usually have to wait longer for cadaver kidneys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a history of prior graft loss from BK virus poses a particular concern because of the risk of recurrence, retransplantation may be considered. We recommend confirming the absence of viral replication prior to retransplant, although two successful cases of retransplant during active viremia have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Infection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\", section on 'Kidney retransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of renal disease should be documented as part of the initial evaluation if possible, since the risk of recurrence of the primary renal disease in the transplanted kidney varies depending upon the specific disease.",
"   </p>",
"   <p>",
"    Although the type of original kidney disease is not a contraindication to transplantation, the physician should be aware that many diseases can recur in the allograft and, in some cases, are more likely to lead to graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Examples of disease that more commonly recur include focal segmental glomerulosclerosis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, IgA nephropathy, diabetic nephropathy, and primary hyperoxaluria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is, however, no disease in which recurrence in the transplant is so common and so predictive of graft failure that transplantation should not be performed.",
"   </p>",
"   <p>",
"    Recurrent disease, particularly if rapid, may influence whether to use a living donor in retransplant attempts. As an example, among patients with primary focal and segmental glomerulosclerosis (FSGS), recipients who develop recurrent disease in the first transplant are at very high risk (up to 75 percent) for recurrence in subsequent allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. If the first graft is lost to recurrent FSGS, the chance of recurrence in subsequent transplant attempts markedly increases. Among such patients, both the potential donor and recipient should be advised of the increased risk of recurrent disease.",
"   </p>",
"   <p>",
"    Certain diseases warrant specific procedures. As an example, a patient who has primary oxalosis should be considered for combined liver-kidney transplantation, rather than single organ kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link&amp;anchor=H58182972#H58182972\">",
"     \"Primary hyperoxaluria\", section on 'Transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, optimal timing of transplantation may depend on the cause of end-stage renal disease. In anti-GBM disease, lupus nephritis, vasculitis, and thrombotic microangiopathy, it is recommended to delay transplantation until disease is quiescent for 6 to 12 months on minimum or no immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=see_link\">",
"     \"Anti-GBM antibody disease: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=see_link&amp;anchor=H3#H3\">",
"     \"End-stage renal disease due to lupus nephritis\", section on 'Issues related to renal transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H21#H21\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Renal transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiphospholipid syndrome and the kidney\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with scleroderma may be transplant candidates if disease is quiescent and limited extra-renal involvement is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H25#H25\">",
"     \"Scleroderma renal crisis\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abnormal lower urinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal lower urinary tract may be a barrier to successful transplantation. A pretransplant evaluation to assess the lower urinary tract may be required in addition to the baseline examination discussed previously. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Initial data collection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following lower urinary tract studies may be utilized in potential renal transplant recipients who have a urologic history [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Voiding cystourethrogram with or without urodynamics for those with voiding dysfunction, bladder augmentation or substitution, history of recurrent urinary tract infection, pyelonephritis or reflux",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inconclusive findings on baseline ultrasonography.",
"     </li>",
"     <li>",
"      Urine or bladder wash cytology in those with a history of exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or irritative symptoms upon voiding.",
"     </li>",
"     <li>",
"      Cystoscopy for patients with possible malignancy of the lower urinary tract.",
"     </li>",
"     <li>",
"      Bladder biopsy for patients with suspected malignancy or fibrosis of the bladder.",
"     </li>",
"     <li>",
"      Loopogram for patients with an ileal conduit to document the length and course of conduit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretransplant recipient nephrectomy is not routinely recommended. However, there are conditions in which the procedure may be considered. Such conditions include autosomal dominant polycystic kidney disease (ADPKD), recurrent infection with nephrolithiasis, and massive proteinuria in children.",
"   </p>",
"   <p>",
"    There are conflicting data concerning the benefits of nephrectomy in patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In general, pretransplant nephrectomy is reserved for those with recurrent, symptomatic, cyst-related complications or kidney size that would make the transplant surgery difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of recurrent pyelonephritis with vesicoureteral reflux has traditionally been considered an indication for pretransplant nephrectomy. However, there is a paucity of evidence to suggest that bilateral nephrectomy lowers the incidence of posttransplant infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the requirement for immunosuppression, pretransplant nephrectomies may be a reasonable therapeutic option for patients with recurrent infection occurring in association with nephrolithiasis. However, the benefit of nephrectomy among such patients is unclear.",
"   </p>",
"   <p>",
"    Bilateral nephrectomy is now largely abandoned for the control of hypertension; it was previously infrequently used for refractory hypertension when potent antihypertensive agents were not yet widely available. Since the procedure is associated with significant morbidity and mortality, nephrectomy is currently considered the last option for control of otherwise refractory hypertension.",
"   </p>",
"   <p>",
"    Nephrectomy is not indicated for the prevention of recurrent disease, and, if performed, may actually enhance recurrence. In one study, for example, a higher rate of recurrent FSGS and membranous nephropathy was observed with native nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with massive proteinuria, as observed in congenital nephrotic syndrome of the Finnish type, may benefit from pretransplant nephrectomy. In this setting, nephrectomy decreases mortality, allows for growth, and markedly reduces the risk of renal transplant thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. It is unknown whether pretransplant nephrectomy also reduces the risk of thrombosis in adults with massive proteinuria. Additional indications for nephrectomy in children prior to transplantation are discussed separately. Preemptive nephrectomy should be considered in congenital syndromes associated with increased risk of Wilms tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A post-nephrectomy waiting time of six weeks is usually recommended to ensure that the wound is not infected and the patient has adequately healed prior to the transplant surgery. However, some surgeons prefer to perform both operations at the same time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to evaluate the presence and severity of coronary disease, heart failure, valvular disease and arrhythmias prior to transplantation. Cardiovascular disease is the leading cause of death after kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], and is also a major cause of morbidity and mortality in patients still on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of cardiac testing are to assist in determining transplant candidacy and to identify patients who might benefit from pre-operative cardiac intervention (eg, revascularization), and aggressive risk factor modification to decrease perioperative and posttransplant cardiac events.",
"   </p>",
"   <p>",
"    Diabetic patients are at a particularly high risk for development of cardiovascular disease, and special issues related to diabetic patients are discussed in detail separately [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation begins with a history, physical examination, electrocardiogram, and chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/37\">",
"     37",
"    </a>",
"    ]. Based upon the findings of this initial assessment, noninvasive testing is usually performed in patients with",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of heart disease, previous history of coronary heart disease (such as myocardial infarction),",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of heart failure, diabetes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple major risk factors for heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Risk factors include increased age (&gt;45 years in males and &gt;55 years in females), hypertension, dyslipidemia, diabetes, family history of heart disease, peripheral vascular disease, history of smoking, prolonged duration of chronic kidney disease and dialysis vintage greater than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5,10,39\">",
"     5,10,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninvasive tests have limitations in their ability to detect coronary heart disease in patients with chronic kidney disease, particularly those with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The optimal non-invasive test is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/39\">",
"     39",
"    </a>",
"    ]. A Cochrane review suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography and thallium myocardial perfusion scan both have moderate sensitivity and specificity among kidney transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/41\">",
"     41",
"    </a>",
"    ]. The optimal choice is generally based upon the expertise of the particular medical center [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography may be required in patients with a positive noninvasive test, a previous history of myocardial infarction, unstable angina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high risk of heart disease including those with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5,42\">",
"     5,42",
"    </a>",
"    ]. The decision to proceed with angiography and possible angioplasty or surgery is usually made in conjunction with the patients' cardiologist.",
"   </p>",
"   <p>",
"    The selection of transplant candidates for invasive or noninvasive screening for heart disease is generally based upon risk stratification. However only a few studies have examined whether a risk-stratification screening strategy for heart disease is effective among transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/37,43\">",
"     37,43",
"    </a>",
"    ]. One of the largest retrospective studies reported the outcomes of 514 consecutive candidates for deceased donor kidney transplantation who underwent an evaluation for possible coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients were initially stratified into low and high risk groups based on the presence of clinical features, with increased risk being associated with diabetes, history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of heart disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple risk factors for heart disease (age &ge;45 years, cigarette smoking, dyslipidemia, hypertension, and a history of cerebral or peripheral vascular disease). Nearly 44 percent (224 patients) were considered to be at low risk and did not undergo screening. The remaining high risk group (56 percent) underwent a noninvasive stress test and was examined by a cardiologist. Those with a positive test proceeded to angiography and possible angioplasty or surgery. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among low risk patients who were not screened, the incidence of a cardiovascular event after being placed on the wait list was extremely low (0.5, 3.5, and 5.3 percent at one, three, and five years respectively). This included periods before and after transplantation.",
"     </li>",
"     <li>",
"      Among high risk patients, screening led to prophylactic angioplasty and bypass surgery in 6.2 and 3 percent of patients, respectively.",
"     </li>",
"     <li>",
"      After being placed on the waitlist, 25 low risk patients subsequently underwent testing for the first time and 36 high risk patients underwent retesting. This resulted in angioplasty and bypass surgery in 9.8 and 1.6 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, this strategy effectively avoided unnecessary screening studies in over 40 percent of patients, a group in whom the risk of adverse events was low. This strategy needs to be further tested in well designed trials before it is implemented however.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17838439\">",
"    <span class=\"h3\">",
"     Patients with known heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known coronary heart disease are eligible for transplantation but require careful evaluation. We agree with the 2005 Canadian Society for Transplantation Guidelines, which suggested that the following patients with known coronary heart disease may be eligible for kidney transplantation (",
"    <a class=\"graphic graphic_table graphicRef55418 \" href=\"UTD.htm?15/24/15757\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68334 \" href=\"UTD.htm?42/9/43164\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic low risk patients",
"     </li>",
"     <li>",
"      Asymptomatic patients in whom non-invasive testing is negative",
"     </li>",
"     <li>",
"      Patients on appropriate medical therapy with angiographic results showing non-critical disease",
"     </li>",
"     <li>",
"      Patients in whom successful interventions have been performed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the history, physical examination, chest x-ray and electrocardiogram, the patient with evidence of or an increased risk for left ventricular dysfunction or valvular disease should undergo echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. If possible, the cause of myocardial dysfunction should be corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)(",
"    <a class=\"graphic graphic_table graphicRef68334 \" href=\"UTD.htm?42/9/43164\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Combined kidney-heart transplantation may be offered to those who may require transplantation of both organs within a few years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .) A number of such combined transplantation from a single donor has thus far been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Among potential recipients, it is extremely important to exclude the presence of reversible impairment of either organ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased incidence of atherosclerotic cerebrovascular disease after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, older patients with risk factors such as hypertension, cigarette smoking, and hypercholesterolemia should be carefully examined for evidence of carotid stenosis. Patients with a history of transient ischemic attacks should be evaluated by a neurologist and receive carotid Doppler studies. If carotid surgery is indicated, it should be done prior to transplantation.",
"   </p>",
"   <p>",
"    In potential recipients with ADPKD, a screening MRA should be performed in those with history of headaches or a family history of aneurysm. Those found to have aneurysms &gt;10 mm in diameter warrant neurosurgical evaluation prior to transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link&amp;anchor=H7#H7\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Indications for intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral vascular disease is present or develops after surgery in a significant number of renal transplant recipients, especially among diabetic recipients. In one retrospective study, the incidence of severe peripheral vascular disease defined by requirement for bypass, major amputation, claudication or angioplasty was 4.2 and 5.9 percent at 5 and 10 years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/47\">",
"     47",
"    </a>",
"    ]. In another retrospective study of 43,427 transplant recipients, the incidence of peripheral vascular disease identified by Medicare claims data was 20 percent among diabetic patients and 5 percent among non-diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral vascular disease is associated with an increased risk of amputation (particularly in diabetic patients), allograft ischemia, significant morbidity, and poor patient survival. In the study cited above, peripheral vascular disease was associated with almost a twofold increase in patient mortality following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/48\">",
"     48",
"    </a>",
"    ]. In another report, among 129 prospective renal allograft recipients (34 and 95 with and without diabetes, respectively) peripheral vascular disease established by noninvasive Doppler vascular studies at the time of transplantation was associated with increased risk of proximal foot amputations and increased patient mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/47,49\">",
"     47,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although routine screening for peripheral vascular disease is not indicated, noninvasive Doppler vascular studies are useful in patients with diabetes, a history of claudication, or poor peripheral pulses on examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. Such studies may identify patients with significant peripheral vascular disease.",
"   </p>",
"   <p>",
"    Iliac calcification may also be assessed in high risk patients using noncontrast CT of the",
"    <span class=\"nowrap\">",
"     abdomen/pelvis.",
"    </span>",
"    This information may be utilized to determine optimal allograft placement.",
"   </p>",
"   <p>",
"    Severe bilateral iliac or lower-extremity arterial disease, or large abdominal aneurysms that are not amenable to surgical correction, are a contraindication to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of information concerning the optimal pretransplant evaluation of patients with respiratory disease. At minimum, the evaluation should be consistent with that for the general population who undergo a preoperative pulmonary assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The presence of dialysate in the abdomen in patients undergoing chronic peritoneal dialysis does not appear to affect the results of pulmonary function studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2005 Canadian Transplant guidelines which suggest that patients with the following clinical features should not be candidates for kidney transplantation (",
"    <a class=\"graphic graphic_table graphicRef81028 \" href=\"UTD.htm?33/26/34220\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Home oxygen therapy requirement",
"     </li>",
"     <li>",
"      Uncontrolled asthma",
"     </li>",
"     <li>",
"      Severe cor pulmonale",
"     </li>",
"     <li>",
"      Severe chronic obstructive pulmonary",
"      <span class=\"nowrap\">",
"       disease/pulmonary",
"      </span>",
"      <span class=\"nowrap\">",
"       fibrosis/restrictive",
"      </span>",
"      disease. This is defined by best FEV1 &lt;25 percent predictive value, PO2 room air &lt;60 mmHg with exercise desaturation SaO2 &lt;90 percent, &gt;4 lower respiratory tract infections in the last 12 months,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      moderate disease with progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients should also discontinue smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"     6",
"    </a>",
"    ], since it increases the risk of allograft loss and patient death. In one study, patients with a 25 pack-year smoking history at the time of transplant had a 30 percent higher risk of allograft failure than those who either had never smoked or had smoked less [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, patients who had quit cigarette smoking more than five years prior to transplant had a 34 percent lower relative risk of graft failure. The enhanced risk of graft failure among smokers was largely due to increased patient death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     CMV and hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations regarding CMV and hepatitis B and C infections are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be free of all active infection before transplantation and consideration should be given to prophylaxis for certain infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those at increased infectious risk post transplant include patients with prior splenectomy, chemotherapy or immunosuppressive history or inherited or acquired immunodeficiencies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most centers exclude patients who test positive for HIV. However, with the current availability of highly active antiretroviral therapy, some centers are reevaluating this policy on a case by case basis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"       \"Solid organ transplantation in HIV-infected individuals\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate transplant recipients should be immunized against influenza, pneumococcus, hepatitis B, and varicella if antibody negative. Vaccination for haemophilus influenza and meningococcus should be considered in asplenic individuals.",
"     </li>",
"     <li>",
"      The patient with a positive chest x-ray or PPD should be evaluated and treated adequately before undergoing transplantation.",
"     </li>",
"     <li>",
"      Dental infections should be treated prior to transplantation.",
"     </li>",
"     <li>",
"      As previously mentioned, serologic testing is also performed for cytomegalovirus, Epstein Barr virus, and hepatitis B and C virus. Issues surrounding infection and malignancy associated with these viruses and kidney transplant are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=see_link\">",
"       \"Hepatitis B virus infection in renal transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"       \"Hepatitis C virus infection and renal transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend delaying retransplantation after graft loss due to BK virus nephropathy until viral replication is absent; there is no consensus regarding the need for transplant nephrectomy in this scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\", section on 'Kidney retransplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of peptic ulcer disease, cholelithiasis, and diseases of the colon may place patients at increased risk posttransplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with active peptic ulcer disease may have exacerbation after renal transplantation. Such patients should be adequately treated with resolution of lesions confirmed by endoscopy prior to transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/54\">",
"       54",
"      </a>",
"      ]. All transplant recipients should be prophylactically treated with H2 receptor antagonists or proton pump inhibitors, especially in the early posttransplant period when the steroid dose is highest [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transplant recipients with diabetes have a high incidence of cholelithiasis. In one study, for example, 30 percent of pancreas transplant recipients, 27 percent of diabetic renal transplant recipients, and only 12 percent of nondiabetic renal transplant recipients had gallstones at a mean interval of 13 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/56\">",
"       56",
"      </a>",
"      ]. Prophylactic cholecystectomy is not routinely performed however [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with known colonic polyps, diverticular disease, inflammatory bowel disease or at high risk for colon cancer (ie, family history of colon cancer or familial adenomatous polyposis) should be evaluated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"       5",
"      </a>",
"      ]. Partial resection should be considered in those with extensive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent symptomatic diverticular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression following transplantation favors the growth of malignant cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .) Additionally, many cancers are associated with viral infections occasionally present in transplant recipients (eg, HCV and hepatocellular carcinoma). Higher incidence of certain malignancies is greater in dialysis patients compared with the general population. Given these factors and the increased mortality after recurrence in the transplant recipient, pretransplant screening is warranted.",
"   </p>",
"   <p>",
"    Patients undergoing chronic dialysis therapy are at an increased risk of developing renal cell, bladder, cervical, thyroid, and liver cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/4,59\">",
"     4,59",
"    </a>",
"    ]. Renal and bladder cancer risk is particularly increased in patients with toxic, infectious, or obstructive nephropathies.",
"   </p>",
"   <p>",
"    We screen for renal cancers by renal ultrasound prior to transplantation, although some clinicians only perform ultrasound on patients who have been on dialysis for a prolonged time (ie, over ten years). In one series, use of ultrasound in 206 patients awaiting renal transplantation resulted in the detection of 8 renal cell carcinomas (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link&amp;anchor=H5#H5\">",
"     \"Acquired cystic disease of the kidney in adults\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with high risk for bladder cancer, including those exposed to industrial carcinogens or previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , may be screened using urinalysis, urine cytology, voiding cystourethrogram, or cystoscopy.",
"    <br/>",
"    <br/>",
"    Women should have a Papanicolaou smear performed unless a hysterectomy has been performed. In patients with hepatitis B",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C, screening for hepatocellular carcinoma should include measurement of alpha-fetoprotein and imaging of the liver by ultrasound, CT or MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at high risk for colon cancer should be screened prior to transplant as discussed above. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Initial data collection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Gastrointestinal disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17838597\">",
"    <span class=\"h3\">",
"     Patients with a history of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and most clinical guidelines recommend a waiting period, free of recurrence, of two to five years for most patients with a history of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/4,6,8,14\">",
"     4,6,8,14",
"    </a>",
"    ]. This is to minimize the risk of recurrence due to the enhanced development of micrometastasis by immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/61\">",
"     61",
"    </a>",
"    ]. There are limited data on the extent of the risk of recurrence among transplant recipients; one study found an overall recurrence rate of 22 and 27 percent with treatment before and after transplantation, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/62\">",
"     62",
"    </a>",
"    ]. There is, however, a marked variability in the likelihood of recurrence according to tumor type that determines the recommendations for patients with preexisting tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suggested cancer-free interval prior to transplantation must be individualized based on patient and tumor characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/4,6,8,14,63\">",
"     4,6,8,14,63",
"    </a>",
"    ]. The following recommendations apply to certain tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer with regional node involvement, bilateral disease, or inflammatory histology requires five years without evidence of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/8,63\">",
"       8,63",
"      </a>",
"      ]. A two-year wait may only be considered for in situ lesions (eg, ductal carcinoma in situ).",
"     </li>",
"     <li>",
"      A five year requirement also applies to malignant melanoma and to colorectal carcinoma other than in situ Duke's A or B1 carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/4,8,63\">",
"       4,8,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No waiting period is required for basal or squamous cell carcinoma of the skin, in situ bladder cancer, and all noninvasive papillary tumors of the bladder [",
"      <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/10,63\">",
"       10,63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5475995\">",
"    <span class=\"h2\">",
"     Hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine hematologic assessment of all transplant candidates includes a complete blood count with differential, and measurement of partial thromboplastin time and international normalized ratio (INR). Patients with recurrent miscarriage,",
"    <span class=\"nowrap\">",
"     arterial/venous",
"    </span>",
"    thrombosis, hemodialysis graft or fistula thrombosis, lupus, or prior unexplained graft thrombosis should be evaluated for underlying hypercoagulable state and may require anticoagulation therapy in the perioperative period. Patients with bleeding tendencies should have detailed coagulation studies. Hematologist evaluation and possible bone marrow biopsy should be obtained for transplant candidates with monoclonal gammopathy (to exclude multiple myeloma) or persistently abnormal blood counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with monoclonal gammopathy of undetermined significance (MGUS) should be carefully evaluated to exclude myeloma prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. However transplantation is generally not delayed among patients in whom myeloma has been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of obese patients (such as a body mass index of greater than 35",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    undergo renal transplantation but are at increased risk for graft loss, delayed graft function, surgical complications including poor wound healing and infection, and new-onset diabetes after transplantation. Weight loss prior to transplantation is often recommended, although there are no data that demonstrate a benefit of this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"     5",
"    </a>",
"    ]. Some transplant centers exclude extremely obese patients (such as a BMI greater than 40",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    with referral for consideration for weight loss surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the psychosocial evaluation are to identify behavioral, social",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    financial issues that may influence compliance and outcomes after transplant. Social workers and psychologists trained in the evaluation of transplant candidates can be invaluable in this assessment, with referral for neuropsychiatric assessment if needed. Patients must be able to demonstrate understanding of the potential risks and benefits of transplantation, the need for lifelong immunosuppressive therapy, and the need for compliance with medication and follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Patients with severe cognitive impairment may be acceptable candidates for transplantation provided that adequate caregiver support and supervised medication administration is guaranteed. Patients with mood, anxiety or personality disorders should be referred to psychiatry for treatment in order to improve access to and success after transplantation.",
"   </p>",
"   <p>",
"    Patients with alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substance abuse or those noncompliant with dialysis treatment need to be rehabilitated prior to transplantation. We require that such patients enroll in a rehabilitation program, and remain drug or alcohol free confirmed by random drug testing and compliant with the dialysis treatment for at least one year before becoming active on the transplant list.",
"   </p>",
"   <p>",
"    Given the high costs of immunosuppressive therapy, financial resources and insurance coverage for each transplant candidate should be reviewed. Potential financial barriers should be addressed prior to transplant with determination whether transplant is feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RE-EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential kidney transplant recipients must be periodically reassessed given the prolonged wait time for a donor kidney and the significant number of comorbid conditions among this patient population. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5476014\">",
"    <span class=\"h1\">",
"     ALTERNATIVE DONOR OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain candidates on the deceased donor waitlist may benefit from considering alternative options beyond standard criteria donor kidneys. For example, acceptable candidates with hepatitis C may be willing to accept a kidney from a hepatitis C positive donor. Studies have demonstrated comparable graft and patient survival with kidneys from hepatitis C positive donors compared with kidneys from hepatitis C negative donors (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expanded criteria donor kidneys are an alternative for candidates of advanced age or excessive projected waitlist mortality. Such patients include those with diabetes and extensive comorbid conditions or those with limited dialysis options. Expanded criteria donor kidneys may also be considered for highly sensitized candidates who have no living donor options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=see_link&amp;anchor=H12#H12\">",
"     \"The kidney transplant waiting list\", section on 'Expanded donor kidneys'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with an incompatible living donor due to HLA or ABO incompatibility may wish to consider ABO-incompatible donor kidneys using desensitization protocols, or paired kidney exchange programs in addition to the deceased donor waitlist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large percentage of patients initially referred for possible renal transplantation are eventually excluded. In one retrospective study of 409 patients with end-stage renal disease, 125 (31 percent) were determined to be ineligible for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/68\">",
"     68",
"    </a>",
"    ]. Reasons for exclusion included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical contraindication &mdash; 46 percent",
"     </li>",
"     <li>",
"      Patient declined &mdash; 25 percent",
"     </li>",
"     <li>",
"      Obesity &mdash; 10 percent",
"     </li>",
"     <li>",
"      Death &mdash; 6 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Insurance/financial",
"      </span>",
"      considerations &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major medical contraindications were heart disease (38 percent), noncompliance (28 percent), and cancer (12 percent).",
"   </p>",
"   <p>",
"    Many patients, however, may not even be referred for evaluation for transplantation. Among 426,489 patients who started dialysis between 2005 and 2009, 12.5 percent had reportedly not been assessed for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/69\">",
"     69",
"    </a>",
"    ]. The reasons for this are unclear but discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Possible referral bias'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Possible referral bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related issue is whether gender, race, or economic factors influence the decision of physicians both to refer patients for a kidney transplant or to ultimately perform such an operation. A number of studies have shown that women, African-Americans, Hispanics, Native Americans, patients dialyzed in for-profit centers, and patients without private insurance are less likely to report having been assessed for transplantation, placed on a waiting list or transplanted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/69-78\">",
"     69-78",
"    </a>",
"    ]. As a result, a significant number of viable candidates are not referred for transplantation. This was suggested by one study that showed a large overlapping risk profile among patients listed for transplant and those not listed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/70\">",
"     70",
"    </a>",
"    ]. Among 453,429 individuals with end-stage renal disease, one third of candidates listed for transplant had a life expectancy of less than five years; conversely one-third of patients not listed had an estimated survival exceeding five years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     For-profit versus not-for-profit centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;After adjusting for confounding factors, one study utilizing data from the United States Renal Data System (USRDS) found that the possibility of being placed on a waiting list was significantly lower for patients being treated at for-profit centers compared to those being dialyzed at non-for-profit centers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/72\">",
"     72",
"    </a>",
"    ]. This was also observed in a survey of information obtained from CMS 2728 forms (which is a mandatory form submitted for each patient at the time of dialysis initiation), in which, among 236,079 incident ESRD patients, those dialyzed at for-profit centers were less likely to be enrolled on the deceased donor waiting list or receiving a living donor kidney transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/78\">",
"     78",
"    </a>",
"    ]. Approximately 30 percent of patients overall were not informed about transplantation options at the time of referral for dialysis. Patients at for-profit centers were less likely to have not been informed because of medical or psychological contraindications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     United States minority groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of United States minority groups, particularly African-Americans, Native Americans and Hispanics, may be less likely than Caucasians to ultimately undergo a kidney transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. One report of over 1500 patients examined possible racial disparity in the United States via the use of a literature review and an expert panel, which evaluated medical charts and, based upon validated criteria, determined the appropriateness or inappropriateness of an individual for renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/76\">",
"     76",
"    </a>",
"    ]. Utilizing such an opinion, blacks were less likely than whites to be considered appropriate candidates.",
"   </p>",
"   <p>",
"    Furthermore, among those deemed appropriate, blacks were significantly less likely than whites to be referred for evaluation (90 versus 98 percent), placed on a waiting list (71 versus 87 percent), or transplanted (17 versus 52 percent). Similar significant differences favoring whites concerning evaluation, placement on a waiting list, or eventual transplantation were also observed among those deemed inappropriate for transplantation. Compared with non-Hispanic Caucasians, African-Americans are also more likely to receive an organ of lesser quality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/79\">",
"     79",
"    </a>",
"    ]. In the analysis of data from CMS-2728 forms that is cited above, African Americans were also less likely to be enrolled on the deceased donor waiting list or awaiting a living donor kidney transplant at the time of dialysis initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A living donor kidney transplant program in which a home-based education approach is added to conventional standard clinic-based transplant may enhance kidney donation among African-Americans. In a randomized study, this combined approach, compared with a clinic alone education, resulted in significantly more living donor inquires (77 versus 52 percent), living donor evaluations (48 versus 17 percent), and eventual kidney transplantation (45 versus 14 percent) in African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that women are less likely than men to receive a kidney transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/71,74,75,78,81\">",
"     71,74,75,78,81",
"    </a>",
"    ]. In one study, among 33,589 individuals with end-stage renal disease, men had a 20 percent greater covariable-adjusted transplantation rate compared to women (95% CI 1.13-1.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Education level",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, patients with higher education levels may have an advantage in obtaining kidney transplantation. In a study of 3245 incident dialysis patients, those with college degrees were approximately three times more likely than high school graduates to be wait listed or undergo kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/82\">",
"     82",
"    </a>",
"    ]. Although these results must be confirmed, it appears that education level contributes to the disparity in transplant referrals and operations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418037540\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians are reluctant to transplant kidneys into elderly patients for a number of reasons. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal transplantation and the elderly patient\", section on 'Ethics of transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reasons for these findings are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Physicians should not permit personal or cultural bias to limit the therapeutic options for patients with end stage renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369513478\">",
"    <span class=\"h3\">",
"     Patients without private insurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective analysis cited above of 426,489 patients who started dialysis between 2005 and 2009, patients without private insurance were more likely to be reported as not assessed for transplantation (adjusted odds ratio of 1.33, 95% CI 1.28-1.40 for Medicaid) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/55/26490/abstract/69\">",
"     69",
"    </a>",
"    ]. Not being assessed for transplantation at the time of dialysis initiation was associated with not being waitlisted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       \"Patient information: Choosing between dialysis and kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       \"Patient information: Kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864986\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney transplantation is the treatment of choice for end-stage renal disease. Transplantation should be discussed with all patients with irreversible and progressive chronic kidney disease. Patients who are interested in transplantation with no known contraindications should be referred to a transplantation program when estimated GFR (glomerular filtration rate) is less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. Patients with a potential contraindication to transplantation should be individually discussed with a transplant center to determine candidacy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H255110068\">",
"       'Timing of transplantation referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation of the recipient should include a thorough medical, surgical and psychosocial history, a detailed physical examination and laboratory evaluation. Potential sensitization risks should be evaluated including history of blood or platelet transfusion, pregnancies, and previous transplants. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial data collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to transplantation include current infection, active malignancy, chronic illness with shortened life expectancy, active substance abuse, and reversible renal failure. In addition, there are numerous relative indications that require careful evaluation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is particularly important to evaluate the presence and severity of heart disease prior to transplantation in order to determine transplant candidacy and to identify patients who might benefit from pre-operative cardiac intervention and aggressive risk factor modification. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a history of cancer should undergo a waiting period, free of recurrence, of two to five years prior to transplantation. The required cancer-free interval prior to transplantation is dependent upon patient and tumor characteristics. Cancers that require a five-year cancer-free interval include breast cancer with regional node involvement, bilateral disease, or inflammatory histology, malignant melanoma, and colorectal carcinoma (other than in situ Duke's A or B1 carcinoma). No waiting period is required for basal or squamous cell carcinoma of the skin, in situ bladder cancer, and all noninvasive papillary tumors of the bladder. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain candidates (including hepatitis C positive or elderly patients) may benefit from considering alternative options beyond standard criteria donor kidneys such as a kidney from a hepatitis C positive donor, or an expanded criteria donor kidney. Other options include an ABO-incompatible donor kidney, desensitization protocols to allow HLA-incompatible transplant, or paired kidney exchange programs. (See",
"      <a class=\"local\" href=\"#H5476014\">",
"       'Alternative donor options'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"       \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/1\">",
"      Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/2\">",
"      Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/3\">",
"      Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/4\">",
"      The evaluation of renal transplant candidates. Clinical Practice Guidelines. Am J Transplant 2001; 2(Suppl 1):5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/5\">",
"      Bunnapradist S, Danovitch GM. Evaluation of adult kidney transplant candidates. Am J Kidney Dis 2007; 50:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/6\">",
"      Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/7\">",
"      Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/8\">",
"      Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/9\">",
"      Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/10\">",
"      Abbud-Filho M, Adams PL, Alber&uacute; J, et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007; 83:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/11\">",
"      Barry JM. Kidney transplantation into patients with abnormal bladders. Transplantation 2004; 77:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/12\">",
"      Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010; 5:1114.",
"     </a>",
"    </li>",
"    <li>",
"     McKay, DB, Milford, EL, Sayegh, MH. Clinical aspects of renal transplantation. In: The Kidney, 5th ed, Brenner, BM, Rector, FC (Eds), Saunders, Philadelphia, 1995.",
"    </li>",
"    <li>",
"     Evaluation of potential renal transplantation. In: Handbook of Kidney Transplantation, 4th edition, Danovitch, GM (Ed), Lippincott Williams and Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/15\">",
"      Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/16\">",
"      Ismail N, Hakim RM, Helderman JH. Renal replacement therapies in the elderly: Part II. Renal transplantation. Am J Kidney Dis 1994; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     The 2008 SRTR report on the state of transplantation. Accessed February, 2010. www.ustransplant.org/annual_reports.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/18\">",
"      Vivas CA, Hickey DP, Jordan ML, et al. Renal transplantation in patients 65 years old or older. J Urol 1992; 147:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/19\">",
"      Tapson JS, Rodger RS, Mansy H, et al. Renal replacement therapy in patients aged over 60 years. Postgrad Med J 1987; 63:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/20\">",
"      Ramos EL. Recurrent diseases in the renal allograft. J Am Soc Nephrol 1991; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/21\">",
"      Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am J Kidney Dis 1994; 24:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/22\">",
"      Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/23\">",
"      Briggs JD, Jones E. Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/24\">",
"      Striegel JE, Sibley RK, Fryd DS, Mauer SM. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int Suppl 1986; 19:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/25\">",
"      Lewis EJ. Recurrent focal sclerosis after renal transplantation. Kidney Int 1982; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/26\">",
"      Brazda E, Ofner D, Riedmann B, et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann Transplant 1996; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/27\">",
"      Knispel HH, Kl&auml;n R, Offermann G, Miller K. Transplantation in autosomal dominant polycystic kidney disease without nephrectomy. Urol Int 1996; 56:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/28\">",
"      Wagner MD, Prather JC, Barry JM. Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease. J Urol 2007; 177:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/29\">",
"      Erturk E, Burzon DT, Orloff M, Rabinowitz R. Outcome of patients with vesicoureteral reflux after renal transplantation: the effect of pretransplantation surgery on posttransplant urinary tract infections. Urology 1998; 51:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/30\">",
"      Odorico JS, Knechtle SJ, Rayhill SC, et al. The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 1996; 61:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/31\">",
"      Savage JM, Jefferson JA, Maxwell AP, et al. Improved prognosis for congenital nephrotic syndrome of the Finnish type in Irish families. Arch Dis Child 1999; 80:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/32\">",
"      Slaughenhoupt BL, Lohrasbi FF, Harrison HL, Van Savage JG. Urologic management of congenital nephrotic syndrome of the Finnish type. Urology 1998; 51:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/33\">",
"      Braun WE. Long-term complications of renal transplantation. Kidney Int 1990; 37:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/34\">",
"      Mahoney, J, Caterson, R, Pollock, C, et al. Coronary artery disease is the major late complication of successful transplantation. Clin Transplant 1990; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     Rostand, S, Rutsky, E. Coronary artery disease in end-stage renal disease. In: Principles and Practice of Dialysis, Henrich, WL (Ed), Williams &amp; Wilkins, Baltimore, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/36\">",
"      Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/37\">",
"      Kasiske BL, Malik MA, Herzog CA. Risk-stratified screening for ischemic heart disease in kidney transplant candidates. Transplantation 2005; 80:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/38\">",
"      Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/39\">",
"      Pilmore H. Cardiac assessment for renal transplantation. Am J Transplant 2006; 6:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/40\">",
"      Holley JL, Fenton RA, Arthur RS. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end-stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991; 90:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/41\">",
"      Wang LW, Fahim MA, Hayen A, et al. Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev 2011; :CD008691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/42\">",
"      De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/43\">",
"      Wong VK, Baker R, Patel J, et al. Renal transplantation to the ovarian vein: a case report. Am J Transplant 2008; 8:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/44\">",
"      Col VJ, Jacquet L, Squifflet JP, et al. Combined heart-kidney transplantation: report on six cases. Nephrol Dial Transplant 1998; 13:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/45\">",
"      Kocher AA, Schlechta B, Kopp CW, et al. Combined heart and kidney transplantation using a single donor: a single center's experience with nine cases. Transplantation 1998; 66:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/46\">",
"      Adams HP Jr, Dawson G, Coffman TJ, Corry RJ. Stroke in renal transplant recipients. Arch Neurol 1986; 43:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/47\">",
"      Sung RS, Althoen M, Howell TA, Merion RM. Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation 2000; 70:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/48\">",
"      Snyder JJ, Kasiske BL, Maclean R. Peripheral arterial disease and renal transplantation. J Am Soc Nephrol 2006; 17:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/49\">",
"      M&auml;kisalo H, Lep&auml;ntalo M, Halme L, et al. Peripheral arterial disease as a predictor of outcome after renal transplantation. Transpl Int 1998; 11 Suppl 1:S140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/50\">",
"      Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/51\">",
"      Ferguson GT. Recommendations for the management of COPD. Chest 2000; 117:23S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/52\">",
"      Ulubay G, Sezer S, Ulasli S, et al. Respiratory evaluation of patients on continuous ambulatory peritoneal dialysis prior to renal transplantation. Clin Nephrol 2006; 66:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/53\">",
"      Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/54\">",
"      Chen KJ, Chen CH, Cheng CH, et al. Risk factors for peptic ulcer disease in renal transplant patients--11 years of experience from a single center. Clin Nephrol 2004; 62:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/55\">",
"      Sk&aacute;la I, Mareckov&aacute; O, V&iacute;tko S, et al. Prophylaxis of acute gastroduodenal bleeding after renal transplantation. Transpl Int 1997; 10:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/56\">",
"      Lowell JA, Stratta RJ, Taylor RJ, et al. Cholelithiasis in pancreas and kidney transplant recipients with diabetes. Surgery 1993; 114:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/57\">",
"      Kao LS, Flowers C, Flum DR. Prophylactic cholecystectomy in transplant patients: a decision analysis. J Gastrointest Surg 2005; 9:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/58\">",
"      Meka M, Potdar S, Benotti P, et al. Role of ultrasound screening for gallbladder disease in pretransplant patients. Am Surg 2008; 74:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/59\">",
"      Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/60\">",
"      Gulanikar AC, Daily PP, Kilambi NK, et al. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 1998; 66:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/61\">",
"      Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc 2001; 33:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/62\">",
"      Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/63\">",
"      Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/64\">",
"      Trofe J, Buell JF, Woodle ES, et al. Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation 2004; 78:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/65\">",
"      Scandling JD. Kidney transplant candidate evaluation. Semin Dial 2005; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/66\">",
"      Levinson, J, Olbrisch, M. Psychosocial evaluation of organ transplant candidates. A comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychomatics 1993; 34:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/67\">",
"      Dobbels F, Vanhaecke J, Dupont L, et al. Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation 2009; 87:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/68\">",
"      Holley JL, Monaghan J, Byer B, Bronsther O. An examination of the renal transplant evaluation process focusing on cost and the reasons for patient exclusion. Am J Kidney Dis 1998; 32:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/69\">",
"      Johansen KL, Zhang R, Huang Y, et al. Association of race and insurance type with delayed assessment for kidney transplantation among patients initiating dialysis in the United States. Clin J Am Soc Nephrol 2012; 7:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/70\">",
"      Schold JD, Srinivas TR, Kayler LK, Meier-Kriesche HU. The overlapping risk profile between dialysis patients listed and not listed for renal transplantation. Am J Transplant 2008; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/71\">",
"      Alexander GC, Sehgal AR. Barriers to cadaveric renal transplantation among blacks, women, and the poor. JAMA 1998; 280:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/72\">",
"      Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/73\">",
"      Ayanian JZ, Cleary PD, Weissman JS, Epstein AM. The effect of patients' preferences on racial differences in access to renal transplantation. N Engl J Med 1999; 341:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/74\">",
"      Garg PP, Furth SL, Fivush BA, Powe NR. Impact of gender on access to the renal transplant waiting list for pediatric and adult patients. J Am Soc Nephrol 2000; 11:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/75\">",
"      Schaubel DE, Stewart DE, Morrison HI, et al. Sex inequality in kidney transplantation rates. Arch Intern Med 2000; 160:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/76\">",
"      Epstein AM, Ayanian JZ, Keogh JH, et al. Racial disparities in access to renal transplantation--clinically appropriate or due to underuse or overuse? N Engl J Med 2000; 343:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/77\">",
"      Sequist TD, Narva AS, Stiles SK, et al. Access to renal transplantation among American Indians and Hispanics. Am J Kidney Dis 2004; 44:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/78\">",
"      Kucirka LM, Grams ME, Balhara KS, et al. Disparities in provision of transplant information affect access to kidney transplantation. Am J Transplant 2012; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/79\">",
"      Schold JD, Kaplan B, Chumbler NR, et al. Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol 2005; 16:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/80\">",
"      Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. A randomized trial of a home-based educational approach to increase live donor kidney transplantation: effects in blacks and whites. Am J Kidney Dis 2008; 51:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/81\">",
"      Bloembergen WE, Mauger EA, Wolfe RA, Port FK. Association of gender and access to cadaveric renal transplantation. Am J Kidney Dis 1997; 30:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/82\">",
"      Schaeffner ES, Mehta J, Winkelmayer WC. Educational level as a determinant of access to and outcomes after kidney transplantation in the United States. Am J Kidney Dis 2008; 51:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/83\">",
"      Fink JC. Do you need to stay in school to get a kidney transplant? Am J Kidney Dis 2008; 51:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/84\">",
"      Sabatini S. Influence of gender and race on therapeutic options for ESRD patients. Am J Kidney Dis 1997; 30:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/55/26490/abstract/85\">",
"      Milford EL. Organ transplantation--barriers, outcomes, and evolving policies. JAMA 1998; 280:1184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7309 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26490=[""].join("\n");
var outline_f25_55_26490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H864986\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255110068\">",
"      TIMING OF TRANSPLANTATION REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL DATA COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Is age a contraindication?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2427613\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retransplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abnormal lower urinary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17838439\">",
"      - Patients with known heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CMV and hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17838597\">",
"      - Patients with a history of cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5475995\">",
"      Hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RE-EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5476014\">",
"      ALTERNATIVE DONOR OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Possible referral bias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - For-profit versus not-for-profit centers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - United States minority groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Education level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H418037540\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H369513478\">",
"      - Patients without private insurance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864986\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/47/6909\" title=\"table 1\">",
"      Canada Guide timing age kid tx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/24/15757\" title=\"table 2\">",
"      Canada Guide heart dis kid tx 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/9/43164\" title=\"table 3\">",
"      Canada Guide heart dis kid tx 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/26/34220\" title=\"table 4\">",
"      Canada Guide pulm dis kid tx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=related_link\">",
"      Anti-GBM antibody disease: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=related_link\">",
"      Hepatitis B virus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=related_link\">",
"      Renal function and nonrenal solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=related_link\">",
"      Renal transplantation and the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=related_link\">",
"      The kidney transplant waiting list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_55_26491="Prev HD cath infection";
var content_f25_55_26491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of infection with central hemodialysis catheters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement and relocation of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not routinely replace hemodialysis catheters.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of catheter-site dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of administration sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use hemodialysis catheters solely for hemodialysis. Use of hemodialysis catheters for other purposes (eg, administration of fluids, blood/blood products, or parenteral nutrition) should be restricted to circumstances where no alternative vascular access is feasible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hang time for parenteral fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use hemodialysis catheters solely for hemodialysis. Use of hemodialysis catheters for other purposes (eg, administration of fluids, blood/blood products, or parenteral nutrition) should be restricted to circumstances where no alternative vascular access is feasible.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26491=[""].join("\n");
var outline_f25_55_26491=null;
var title_f25_55_26492="Causes of thyroiditis";
var content_f25_55_26492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of thyroiditis according to the presence or absence of pain and tenderness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Synonyms or causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Thyroid pain and tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Subacute thyroiditis",
"       </td>",
"       <td>",
"        Subacute granulomatous thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute nonsuppurative thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        de Quervain's thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infectious thyroiditis",
"       </td>",
"       <td>",
"        Acute or chronic thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation-induced thyroiditis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palpation- or trauma-induced thyroiditis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        No thyroid pain and tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" rowspan=\"3\">",
"        Painless thyroiditis",
"       </td>",
"       <td>",
"        Silent thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        Subacute lymphocytic thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Occurring postpartum",
"       </td>",
"       <td class=\"sublist_other\">",
"        Postpartum thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"4\">",
"        - Associated with drugs",
"       </td>",
"       <td class=\"sublist_other\">",
"        Interferon-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Interleukin-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Tyrosine kinase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Chronic lymphocytic thyroiditis",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Hashimoto's thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Postpartum exacerbation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Postpartum thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone-associated thyroiditis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Fibrous thyroiditis",
"       </td>",
"       <td>",
"        Riedel's thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive thyroiditis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26492=[""].join("\n");
var outline_f25_55_26492=null;
var title_f25_55_26493="Pulmonary artery tracing";
var content_f25_55_26493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery pressure tracing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram shows the demonstrates key features of the pulmonary artery pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components. The peak systolic pressure falls within the electrocardiographic T wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gore, JM, Alpert, JS, Benotti, JR, et al, Handbook of hemodynamic monitoring, 1st edition, Boston, Little Brown &amp; Co, 1985.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26493=[""].join("\n");
var outline_f25_55_26493=null;
var title_f25_55_26494="Chest wall volume vs pressure";
var content_f25_55_26494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    The volume-pressure relationships of the chest wall (pw) and the pressures contributed by the diaphragm (pdi) and abdomen (pab) in the sitting (A) and supine (B) postures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from McCool, FD, Rochester, DF. The lungs and chest Wall diseases. In: textbook of Respiratory Medicine, 2nd ed, Vol 2, Murray, JF, Nadel, JA (Eds), WB Saunders, Philadelphia, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26494=[""].join("\n");
var outline_f25_55_26494=null;
var title_f25_55_26495="Leukotriene modifiers";
var content_f25_55_26495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Leukotriene modifiers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLA",
"     <sub>",
"      2",
"     </sub>",
"     : phospholipase A",
"     <sub>",
"      2",
"     </sub>",
"     ; AA: arachidonic acid; 5-LO: 5-lipoxygenase; FLAP: 5-LO activating protein; LTA",
"     <sub>",
"      4",
"     </sub>",
"     : leukotriene A",
"     <sub>",
"      4",
"     </sub>",
"     ;&nbsp;LTA",
"     <sub>",
"      4",
"     </sub>",
"     H: LTA",
"     <sub>",
"      4",
"     </sub>",
"     hydrolase; LTC",
"     <sub>",
"      4",
"     </sub>",
"     S: LTC",
"     <sub>",
"      4",
"     </sub>",
"     synthetase; LTB",
"     <sub>",
"      4",
"     </sub>",
"     : leukotriene B",
"     <sub>",
"      4",
"     </sub>",
"     arises from the hydrolysis of LTA",
"     <sub>",
"      4",
"     </sub>",
"     by LTA",
"     <sub>",
"      4",
"     </sub>",
"     hydrolase; LTC",
"     <sub>",
"      4",
"     </sub>",
"     : leukotriene C",
"     <sub>",
"      4",
"     </sub>",
"     arises from the conjugation of LTA",
"     <sub>",
"      4",
"     </sub>",
"     with reduced glutathione by LTC",
"     <sub>",
"      4",
"     </sub>",
"     synthetase; LTD",
"     <sub>",
"      4",
"     </sub>",
"     : leukotriene D",
"     <sub>",
"      4",
"     </sub>",
"     arises from LTC",
"     <sub>",
"      4",
"     </sub>",
"     by the rapid removal of glutamic acid in the extracellular microenvironment; LTE",
"     <sub>",
"      4",
"     </sub>",
"     : leukotriene E",
"     <sub>",
"      4",
"     </sub>",
"     arises from LTD",
"     <sub>",
"      4",
"     </sub>",
"     by the further removal of glycine in the extracellular microenvironment; BLT1: receptor for LTB",
"     <sub>",
"      4",
"     </sub>",
"     ,&nbsp;no commercially available inhibitors; BLT2: receptor for LTB",
"     <sub>",
"      4",
"     </sub>",
"     ,&nbsp;no commercially available inhibitors; CysLTS: cys-leukotrienes, LTC",
"     <sub>",
"      4",
"     </sub>",
"     , LTD",
"     <sub>",
"      4",
"     </sub>",
"     , LTE",
"     <sub>",
"      4",
"     </sub>",
"     ; CysLT1: receptor for LTC",
"     <sub>",
"      4",
"     </sub>",
"     , LTD",
"     <sub>",
"      4",
"     </sub>",
"     , LTE",
"     <sub>",
"      4",
"     </sub>",
"     , inhibited by montelukast, pranlukast, and zafirlukast; CysLT2: receptor for LTC",
"     <sub>",
"      4",
"     </sub>",
"     , LTD",
"     <sub>",
"      4",
"     </sub>",
"     , LTE",
"     <sub>",
"      4",
"     </sub>",
"     , but not inhibited by montelukast, pranlukast, or zafirlukast.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_55_26495=[""].join("\n");
var outline_f25_55_26495=null;
